Compound containing aromatic bicyclic ring

By developing IC compounds that can selectively bind and disrupt the interaction between TEAD protein and YAP/TAZ, the problem of difficult inhibition of the interaction between YAP/TAZ and TEAD protein in the prior art has been solved, and effective inhibition of tumor cell proliferation is achieved. A new tumor treatment method.

WO2024235115A1PCT designated stage expired Publication Date: 2024-11-21CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092286
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-07
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit the interaction between YAP/TAZ and TEAD protein, resulting in the challenge of targeting the Hippo signaling pathway in tumor therapy, especially due to the structural flexibility of YAP/TAZ and the difficulty of small molecule interference.

Method used

Developed a new class of IC compounds that indirectly inhibit the activity of YAP by selectively binding and disrupting the interaction of TEAD proteins with YAP and TAZ, and thus indirectly inhibiting the activity of YAP, these compounds and their pharmaceutically acceptable salts are prepared for the treatment of tumor diseases. .

Benefits of technology

Effectively downregulate YAP-dependent and TAZ-dependent transcription, inhibiting the proliferation of tumor cells, provides a new therapeutic strategy targeting the Hippo pathway, and overcomes the difficulty of traditional small molecule interference.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024092286_21112024_PF_FP_ABST
    Figure CN2024092286_21112024_PF_FP_ABST
Patent Text Reader

Abstract

A compound containing an aromatic bicyclic ring, which has a structure of formula IC, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating tumor diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Compounds containing aromatic bicyclic rings

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This disclosure claims the priority and benefits of Chinese Patent Application No. 202310547249.3, Chinese Patent Application No. 202311268745.1, Chinese Patent Application No. 202410070330.1, Chinese Patent Application No. 202410233399.1 and Chinese Patent Application No. 202410561728.5 filed with the National Intellectual Property Administration of China, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present disclosure relates to a compound containing an aromatic bicyclic ring, a preparation method thereof, a pharmaceutical composition containing the compound, and use thereof in treating tumor diseases. Background Art

[0004] The Hippo signaling cascade is a key pathway in cancer biogenesis and tumor maintenance. The Hippo pathway is heavily mutated in many cancer indications through loss-of-function mutations in genes such as NF2. These tumor-promoting mutations lead to constitutive activation of the downstream transcriptional coactivators YAP and TAZ, which drive the expression of numerous pro-survival and pro-proliferation genes through essential interactions with members of the TEAD protein family. TEAD proteins are downstream effectors of the Hippo signaling pathway, regulating cell proliferation and stem cell function. Furthermore, this unrestricted transcriptional program drives enhanced immunosuppression in the tumor microenvironment. Direct inhibition of YAP / TAZ is challenging because YAP / TAZ are intrinsically disordered proteins with a high degree of structural flexibility. Similarly, small molecule compounds have been difficult to interfere with the YAP-TEAD interaction. By targeting this oncogenic pathway, novel small molecule inhibitors have been identified that selectively bind to TEAD and disrupt their YAP and TAZ interactions, thereby downregulating YAP- and TAZ-dependent transcription. TEAD inhibitors prevent TEAD palmitoylation, which is crucial for the interaction between YAP and TEAD. It indirectly inhibits YAP activity by disrupting TEAD function, thereby suppressing the proliferation of tumor cells.

[0005] Summary of the Invention

[0006] The present disclosure provides a compound of formula IC or a pharmaceutically acceptable salt thereof,

[0007] in,

[0008] X 1 、X 2 、X 3 、X4 and X 5 are independently selected from N or CH;

[0009] X a 、X b 、X c 、X d 、X e and X f are independently selected from N or CH optionally substituted by one or more substituents (specifically, are independently selected from N or CH optionally substituted by one substituent);

[0010] X is selected from O, S, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, or the following groups optionally substituted with one or more substituents: NH, -N(C 1-6 Alkyl)-, -NH-C 1-6 Alkyl-, -C 1-6 Alkyl-O-, -C 1-6 Alkyl-S- or -C(O)NH-;

[0011] Every R 1 are independently selected from CN, halogen, or the following groups optionally substituted by one or more substituents: C 1-6 Alkyl, C 2- 6 alkenyl, C 2-6 Alkynyl, R'O-, R'S-, -SF5, R'R”N-, R'OC(O)-, R'C(O)O-, -C(O)NR'R”, R'C(O)NH-, R' S(O)NH-, R'R”NS(O)-, R'S(O)2NH-, R'R”NS(O)2-, R'OC(O)NH-, R'R”NC(O)O-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3- 12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl;

[0012] Every R 2 are independently selected from CN, halogen, =O, or the following groups optionally substituted with one or more substituents: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, R'O-, R'S-, -SF5, R'R”N-, R'OC(O)-, R'C(O)O-, -C(O)NR'R”, R'C(O)NH-, R'R”NS(O)-, R'S(O)NH-, R'R”NS(O)-, R'R”NS(O)2-, R’S(O)2NH-, R’R”NS(O)2-, R’OC(O)NH-, R’R”NC(O)O-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl;

[0013] R' and R" are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl;

[0014] m and n are independently selected from 0, 1, 2, 3, 4 or 5;

[0015] Ring A is selected from 3-12 membered heterocycloalkyl or 3-12 membered heterocycloalkenyl (eg, N-containing heterocycloalkyl or heterocycloalkenyl).

[0016] In some embodiments, the structural unit Selected from

[0017] In some embodiments, the compound of formula IC, or a pharmaceutically acceptable salt thereof, is selected from formula IC-1, or a pharmaceutically acceptable salt thereof,

[0018] Among them, X 1 、X 2 、X 3 、X 4 、X 5 、X a 、X b 、X c 、X d 、X e 、X f , X, R 1 、R 2 The definitions of m, n and ring A are as described in the present disclosure.

[0019] In some embodiments, the structural unit (Ring A) contains the structural fragment -NHC(O)-.

[0020] In some embodiments, the structural unit (Ring A) contains the structural fragment -NHCH2CH2-. In some embodiments, the structural unit (Ring A) contains the structural fragment -NHCH2CH2*- or -*NHCH2CH2-, * indicates that the nitrogen atom or carbon atom at the site is adjacent to the structure For example, when the structure fragment -*NHCH2CH2- is included, it means that the nitrogen atom at this position is connected to the adjacent structure. Connections can be formed For example, when the structural fragment -NHCH2CH2*- is included, it means that the carbon atom at this position is closely related to the adjacent structure. Connections can be formed

[0021] In some embodiments, the structural unit Selected from where X 6 Selected from N or CH, X 7 is selected from NH, O, S or CH2, and X 6 and X 7 At least one of them contains a nitrogen atom.

[0022] In some embodiments, the compound of formula IC or a pharmaceutically acceptable salt thereof is selected from formula IC-2 or a pharmaceutically acceptable salt thereof,

[0023] Among them, X a 、X c , X, R 1 、R 2 , m, n and ring A are as defined in the present disclosure; wherein X 6 Selected from N or CH, X 7 is selected from NH, O, S or CH2, and X 6 and X 7 At least one of them contains a nitrogen atom.

[0024] In some embodiments, when X 6 When N, X 7 is selected from NH, O, S or CH2; when X 7 When NH, X 6 Selected from CH.

[0025] In some embodiments, X a and X c In some embodiments, X is selected from O.

[0026] When R2 When present, it can occur at any position of ring A (provided that the valence bond rules are met), for example R 2 Can happen at X 6 , CH2 or X 7 etc. location.

[0027] In some embodiments, the structural unit Selected from

[0028] In some embodiments, the compound of formula IC or a pharmaceutically acceptable salt thereof is selected from formula IC-3 or a pharmaceutically acceptable salt thereof,

[0029] Among them, X 1 、X 2 、X 3 、X 4 、X 5 、X a 、X b 、X c 、X d 、X e 、X f , X, R 1 、R 2 The definitions of m, n and ring A are as described in the present disclosure.

[0030] The present disclosure provides a compound of formula I or a pharmaceutically acceptable salt thereof,

[0031] in,

[0032] X 1 、X 2 、X 3 、X 4 and X 5 are independently selected from N or CH;

[0033] X a 、X b 、X c 、X d 、X e and X f are independently selected from N or CH optionally substituted by one or more substituents (specifically, are independently selected from N or CH optionally substituted by one substituent);

[0034] X is selected from O, S, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, or the following groups optionally substituted with one or more substituents: NH, -N(C 1-6Alkyl)-, -NH-C 1-6 Alkyl-, -C 1-6 Alkyl-O-, -C 1-6 Alkyl-S- or -C(O)NH-;

[0035] Every R 1 are independently selected from CN, halogen, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1- 6 alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3- 12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl;

[0036] Every R 2 are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3- 12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl;

[0037] m and n are independently selected from 0, 1, 2, 3, 4 or 5;

[0038] Ring A is selected from 3-12 membered heterocycloalkyl or 3-12 membered heterocycloalkenyl.

[0039] In some embodiments, X 1 、X 2 、X 3 、X 4 and X 5 are independently selected from N or CH.

[0040] In some embodiments, X 1 、X 2 、X 3 、X 4 and X 5 are independently selected from N or CH, X 1 、X 2 、X 3 、X 4 and X 5 Optionally one or two of X are selected from N. In some embodiments, X 1 、X 2 、X 3 、X 4 and X 5 are independently selected from N or CH, X 1 、X 2 、X 3 、X 4 and X 5 One of X is selected from N. In some embodiments, X 1 、X 2 、X 3 、X 4 and X 5 are independently selected from N or CH, X 1 、X 2 、X 3、X 4 and X 5 In some embodiments, two of X are selected from N. 1 、X 2 、X 3 、X 4 and X 5 Selected from CH.

[0041] In some embodiments, X a 、X b 、X c 、X d or X e are independently selected from N or CH, X, which are optionally substituted by one or more (one) substituents f In some embodiments, wherein the one or more substituents are selected from R a , R a The definition of is as described in this disclosure.

[0042] In some embodiments, X a 、X b 、X c 、X d 、X e and X f are independently selected from N or optionally substituted by one or more (one) R a substituted CH, the R a Selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl)2N-.

[0043] In some embodiments, the R a Selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1- 6-alkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1- 6-alkyl NH- or (C 1-6 Alkyl)2N-.

[0044] In some embodiments, the R a Selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1- 3 alkyl) 2N-.

[0045] In some embodiments, the R a Selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl) 2N-, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH- or (C 1-6 alkyl)2N- is optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1-3 Alkyl)2N-.

[0046] In some embodiments, the R a Selected from CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4Alkyl O-, C 1- 4-alkyl S-、-SF5、C 1-4 Alkyl NH- or (C 1-4 Alkyl) 2N-, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH- or (C 1-4 alkyl)2N- is optionally substituted with one or more of the following: CN, halogen, OH or NH2.

[0047] In some embodiments, the R a Selected from CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl or -SF5, the C 1- 4 alkyl, C 2-4 Alkenyl or C 2-4 Alkynyl groups are optionally substituted with one or more of the following groups: CN, halogen, OH, or NH2.

[0048] In some embodiments, the R a Selected from CN, halogen, OH, NH2, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl or -SF5, the C 1- 3 alkyl, C 2-3 Alkenyl or C 2-3 Alkynyl groups are optionally substituted with one or more of the following groups: CN, halogen, OH, or NH2.

[0049] In some embodiments, the R a Selected from CN, halogen, OH, NH2 or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: CN, halogen, OH or NH2.

[0050] In some embodiments, the R a Selected from CN, halogen, OH, NH2 or C 1-3 In some embodiments, the R a Selected from C 1-6 In some embodiments, the R a Selected from C 1-3 In some embodiments, the R a Selected from methyl.

[0051] In some embodiments, X a 、X b 、X c 、X d 、X e and X f are independently selected from CH or N.

[0052] In some embodiments, X a 、X b 、X c 、X d 、X e and X f are independently selected from CH or N, X a 、X b 、X c 、X d 、X e and X f Optionally one or two are selected from N.

[0053] In some embodiments, X b 、X d 、X e and X f are independently selected from CH, X a and X c are independently selected from CH or N, said CH being optionally replaced by one or more R a replace.

[0054] In some embodiments, X b 、X d 、X e and X f are independently selected from CH, X a and X c are independently selected from CH or N.

[0055] In some embodiments, X a 、X b 、X d 、X e and X f are independently selected from CH, X c Selected from N.

[0056] In some embodiments, X b 、X d 、X e and X f are independently selected from CH, X a and X c are independently selected from N.

[0057] In some embodiments, X a 、Xb 、X c 、X d 、X e and X f Selected from CH.

[0058] In some embodiments, when X b When selected from CH, the CH is optionally replaced by R a replace.

[0059] In some embodiments, the structural unit Selected from optionally one or more R a Substituted with the following groups: In some embodiments, the structural unit Selected from In some embodiments, the structural unit Selected from In some embodiments, the structural unit Selected from

[0060] In some embodiments, X is selected from O, S, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, or the following groups optionally substituted with one or more substituents: NH, -N(C 1-3 Alkyl)-, -NH-C 1-3 Alkyl-, -C 1-3 Alkyl-O-, -C 1-3 In some embodiments, X is selected from O, S, or the following groups optionally substituted with one or more substituents: NH or -N(C 1-3 alkyl)-.

[0061] In some embodiments, X is selected from O, S, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, NH, -N(C 1-6 Alkyl)-, -NH-C 1-6 Alkyl-, -C 1-6 Alkyl-O-, -C 1-6 In some embodiments, X is selected from O, S, NH, -N(C 1-3 Alkyl)-, -NH-C 1-3 Alkyl-, -C 1-3 Alkyl-O-, -C 1-3 In some embodiments, X is selected from O, S, NH or -N(C 1-3In some embodiments, X is selected from O, S, or NH. In some embodiments, X is selected from O. In some embodiments, X is selected from O, S, -S(O)-, -S(O)2-, NH, or -N(C 1-6 alkyl)-; X a 、X b 、X c 、X d 、X e and X f In some embodiments, X is selected from O, S, -S(O)-, -S(O)2-, NH or -N(C 1-3 alkyl)-; X a 、X b 、X c 、X d 、 X e and X f In some embodiments, X is selected from O, S, NH or -N(C 1-3 alkyl)-; X a 、X b 、X c 、X d 、X e and X f In some embodiments, X is selected from O, S, or NH; X a 、X b 、X c 、X d 、X e and X f In some embodiments, X is selected from O; X a 、X b 、X c 、X d 、X e and X f Selected from CH.

[0062] In some embodiments, R' and R" are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl.

[0063] In some embodiments, R' and R" are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl.

[0064] In some embodiments, R' and R" are each independently selected from hydrogen or C 1-3In some embodiments, R' and R" are each independently selected from hydrogen, methyl, -CH2CH2NH2 or ethyl.

[0065] In some embodiments, each R 1 are independently selected from CN, halogen, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 alkyl)2N-、HOC(O)-、C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 aryl or 5-12 membered heteroaryl.

[0066] In some embodiments, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1- 6-alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 aryl or 5-12 membered heteroaryl.

[0067] In some embodiments, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl)2N-.

[0068] In some embodiments, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C1-6 Alkyl S-, C 1- 6-alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1- 6-alkyl S-、-SF5、C 1-6 Alkyl NH- or (C 1-6 Alkyl)2N-.

[0069] In some embodiments, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1-3 Alkyl)2N-.

[0070] In some embodiments, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl) 2N-, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH- or (C 1-6 alkyl)2N- is optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1-3 Alkyl)2N-.

[0071] In some embodiments, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH- or (C 1-4 Alkyl) 2N-, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH- or (C 1-4 alkyl)2N- is optionally substituted with one or more of the following: CN, halogen, OH or NH2.

[0072] In some embodiments, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl or -SF5, the C 1-4 Alkyl, C 2-4 Alkenyl or C 2-4 Alkynyl groups are optionally substituted with one or more of the following groups: CN, halogen, OH, or NH2.

[0073] In some embodiments, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl or -SF5, the C 1-3 Alkyl, C 2-3 Alkenyl or C 2-3 Alkynyl groups are optionally substituted with one or more of the following groups: CN, halogen, OH, or NH2.

[0074] In some embodiments, each R 1 are independently selected from CN, halogen, OH, NH2 or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: CN, halogen, OH or NH2.

[0075] In some embodiments, each R 1 Each independently selected from halogenated C 1-6 Alkyl or -SF5.

[0076] In some embodiments, each R 1 Each independently selected from halogenated C 1-3 Alkyl or -SF5.

[0077] In some embodiments, each R 1 are independently selected from fluorinated C 1-3 Alkyl or -SF5.

[0078] In some embodiments, each R 1 are independently selected from fluorinated C 1-3 alkyl.

[0079] In some embodiments, each R 1 Each is independently selected from CF3 or -SF5.

[0080] In some embodiments, each R 1are independently selected from CF3. In some embodiments, each R 2 are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1- 6-alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 aryl or 5-12 membered heteroaryl.

[0081] In some embodiments, at least one R 2 Selected from =O.

[0082] In some embodiments, each R 2 are independently selected from CN, halogen, =O, or the following groups optionally substituted with one or more substituents: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R'O-, R'S-, -SF5, R'R”N-, R'OC(O)-, R'C(O)O-, -C(O)NR'R”, R'C(O)NH-, R'R”NS(O)-, R' S(O)NH-, R'R”NS(O)-, R'R”NS(O)2-, R’S(O)2NH-, R’R”NS(O)2-, R’OC(O)NH-, R’R”NC(O)O-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R'O-, R'S-, -SF5, R'R”N-, R'OC(O)-, R'C(O)O-, -C(O)NR'R”, R'C(O)NH-, R'R”NS(O)-, R' S(O)NH-, R'R”NS(O)-, R'R”NS(O)2-, R’S(O)2NH-, R’R”NS(O)2-, R’OC(O)NH-, R’R”NC(O)O-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-,R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 aryl or 5-12 membered heteroaryl.

[0083] In some embodiments, each R 2 are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 alkyl) 2N-、HOC(O)-、C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 aryl or 5-12 membered heteroaryl.

[0084] In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, HOC(O)-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1- 6-alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-,R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 aryl or 5-12 membered heteroaryl.

[0085] In some embodiments, each R 2are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 alkyl)2N-、HOC(O)-、C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1- 6-alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6 alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6-membered cycloalkenyl, 3-6-membered heterocycloalkenyl, C6 aryl or 5-6-membered heteroaryl is optionally substituted by one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-.

[0086] In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 alkyl)2N-、HOC(O)-、C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, -C(O)NH2, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 1-4 AlkylNHS(O)-, C 1- 4-alkyl S(O)NH-, (C 1-4 Alkyl) 2NS(O)-, C 1-4 Alkyl NHS(O)2-, C 1-4 Alkyl S(O)2NH-, (C 1-4 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4-Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 1-4 AlkylNHS(O)-, C 1-4 Alkyl S(O)NH-, (C 1-4 Alkyl) 2NS(O)-, C 1-4 AlkylNHS(O)2-, C 1-4 Alkyl S(O)2NH-, (C 1-4 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3- 6-membered cycloalkenyl, 3-6-membered heterocycloalkenyl, C6 aryl or 5-6-membered heteroaryl is optionally substituted by one or more of the following groups: CN, halogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-.

[0087] In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 alkyl)2N-、HOC(O)-、C1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, -C(O)NH2, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1- 4-alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, (C 1-4 Alkyl)2N-, C 1-4 Alkyl NH-, -COOH, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylCONH-, C 1-4 Alkyl NHCO- or (C 1-4 Alkyl)2NHCO-.

[0088] In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 1-4 Alkyl O-, C 1-4 Alkyl NH-, (C 1-4 alkyl)2N-、HOC(O)-、C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, -C(O)NH2, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4Alkyl) 2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-4 Alkyl, C 1-4 Alkyl O-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl NH-, -COOH, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-.

[0089] In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, HOC(O)-, C 1-3 Alkyl OC (O) -, -C (O) NH2 or 5-6 membered heterocyclic alkyl, the C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, C 1-3 Alkyl OC (O) - or 5-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkyl NH-, -COOH, or C 1-3 AlkylOC(O)-.

[0090] In some embodiments, each R 2are independently selected from CN, halogen, =O, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, HOC(O)-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl, wherein the methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)-, -C(O)NH2 or 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen (e.g., F or Cl), OH, NH2, methyl, -COOH, C 1-2 Alkyl NH- or CH3OC(O)-.

[0091] In some embodiments, each R 2 They are independently selected from CN, halogen, =O, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, HOC(O)-, CH3OC(O)-, CH3CH2OC(O)-, -C(O)NH2 or 5-membered oxygen-containing heterocycloalkyl, and the methyl, ethyl, CH3CH2NH- or 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: halogen (such as F or Cl), OH, NH2, methyl, -COOH, CH3NH- or CH3OC(O)-.

[0092] In some embodiments, each R 2 are independently selected from halogen (such as F or Cl), =O, OH, NH2, -CH3, -CH2OH, -CH2F, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2C(O)OCH3, -CH2C(O)OH, -CH2NH2, -CH2NHCH3, -OCH3, -NHCH3, -NHCH2CH2NH2, -C(O)OH, -C(O)OCH3, -C(O)OCH2CH3, -C(O)NH2 or

[0093] In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, Rb R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-,R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 alkyl)2NC(O)-、 C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1- 6 alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C1-6 Alkyl NHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl) 2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-.

[0094] In some embodiments, R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl.

[0095] In some embodiments, R b and R c are independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl.

[0096] In some embodiments, R b and R c are independently selected from hydrogen or C 1-3alkyl.

[0097] In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 1-4 AlkylNHS(O)-, C 1-4 Alkyl S(O)NH-, (C 1-4 Alkyl) 2NS(O)-, C 1-4 AlkylNHS(O)2-, C 1-4 Alkyl S(O)2NH-, (C 1-4 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 1-4 AlkylNHS(O)-, C 1-4 Alkyl S(O)NH-, (C 1-4 Alkyl) 2NS(O)-, C 1-4 AlkylNHS(O)2-, C 1-4 Alkyl S(O)2NH-, (C 1-4 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-. In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 3-6Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, (C 1-4 Alkyl)2N-, C 1-4 Alkyl NH-, -COOH, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylCONH-, C 1-4 Alkyl NHCO- or (C 1-4 Alkyl)2NHCO-.

[0098] In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 1-4 Alkyl O-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-4 Alkyl, C 1-4 Alkyl O-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl NH-, -COOH, C1-4 Alkyl OC(O)-, C 1-4 In some embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, C 1-3 Alkyl OC (O) - or 5-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, C 1- 3-membered alkylOC(O)- or 5-6-membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl, -COOH, or C 1-3 AlkylOC(O)-.

[0099] In some embodiments, each R 2 They are independently selected from CN, halogen, =O, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl, and the methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen (such as F or Cl), OH, NH2, methyl, -COOH, or CH3OC(O)-.

[0100] In some embodiments, each R 2 They are independently selected from CN, halogen, =O, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl, and the methyl, ethyl, CH3CH2NH- or 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: halogen (such as F or Cl), OH, NH2, methyl, -COOH, or CH3OC(O)-.

[0101] In some embodiments, each R 2are independently selected from halogen (such as F or Cl), =O, OH, NH2, -CH3, -CH2OH, -CH2F, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2C(O)OCH3, -CH2C(O)OH, -OCH3, -NHCH3, -NHCH2CH2NH2, -C(O)OCH3, -C(O)OCH2CH3 or

[0102] In other embodiments, each R 2 They are independently selected from CN, halogen, =O, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl, and the methyl, ethyl, CH3CH2NH- or 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: OH, NH2, methyl, -COOH, or CH3OC(O)-.

[0103] In other embodiments, each R 2 are independently selected from halogen, =O, OH, NH2, -CH3, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2C(O)OCH3, -CH2C(O)OH, -OCH3, -NHCH3, -NHCH2CH2NH2, -C(O)OCH3, -C(O)OCH2CH3 or

[0104] In other embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl)2N-.

[0105] In other embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3- 6-membered cycloalkenyl, 3-6-membered heterocycloalkenyl, C6 aryl or 5-6-membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1- 6-alkyl S-、-SF5、C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl)2N-.

[0106] In other embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1-3 Alkyl)2N-.

[0107] In other embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl) 2N-, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 alkyl)2N- is optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C1-3 Alkyl NH- or (C 1-3 Alkyl)2N-.

[0108] In some embodiments, R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH- or (C 1-4 Alkyl) 2N-, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH- or (C 1-4 alkyl)2N- is optionally substituted with one or more of the following: CN, halogen, OH or NH2.

[0109] In other embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl or C 2-4 Alkynyl-, the C 1-4 Alkyl, C 2-4 Alkenyl or C 2-4 Alkynyl- is optionally substituted with one or more of the following: CN, halogen, OH, or NH2.

[0110] In other embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-3 Alkyl, C 2-3 Alkenyl or C 2-3 Alkynyl-, the C 1-3 Alkyl, C 2-3 Alkenyl or C 2-3 Alkynyl- is optionally substituted with one or more of the following: CN, halogen, OH, or NH2.

[0111] In other embodiments, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more groups selected from CN, halogen, OH or NH2.

[0112] In other embodiments, each R 2 are independently selected from =O, OH or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more groups selected from OH or NH2.

[0113] In other embodiments, each R 2 are independently selected from =O, OH or C optionally substituted with one or more OH 1-3 Alkyl (e.g. -C 1-3 alkyl-OH).

[0114] In other embodiments, each R 2 Each is independently selected from ═O, OH, —CH 3 or —CH 2 OH.

[0115] In some embodiments, m and n are each independently selected from 0, 1, 2, or 3. In some embodiments, m and n are each independently selected from 1, 2, or 3. In some embodiments, m and n are each independently selected from 1 or 2. In some embodiments, m is selected from 1. In some embodiments, n is selected from 1, 2, or 3. In some embodiments, n is selected from 1 or 2.

[0116] In some embodiments, Ring A is selected from 3-10 membered heterocycloalkyl or 3-10 membered heterocycloalkenyl.

[0117] In some embodiments, Ring A is selected from 3-10 membered heterocycloalkyl or 3-8 membered heterocycloalkenyl.

[0118] In some embodiments, Ring A is selected from 4-10 membered heterocycloalkyl.

[0119] In some embodiments, Ring A is selected from 4-8 or 10-membered heterocycloalkyl.

[0120] In some embodiments, Ring A is selected from 4-6 membered monocyclic heterocycloalkyl, 7-8 membered or 10 membered spiroheterocycloalkyl. In some embodiments, Ring A is selected from 5 membered monocyclic heterocycloalkyl.

[0121] In some embodiments, ring A is selected from pyrrolidinyl, thiazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, diazaspirodecanyl, monooxa-azaspirooctanyl, azetidinyl, monoazaspiroheptyl or oxazolidinyl. In some specific embodiments, ring A is selected from pyrrolidinyl, thiazolidinyl or imidazolidinyl.

[0122] In some embodiments, Ring A is selected from where X t is selected from CH2, NH or O.

[0123] In some embodiments, Ring A is selected from t is selected from 1, 2, 3, 4 or 5, X 8 is selected from CH2, NH, O, or S. In some embodiments, t is selected from 1, 2, or 3. In some embodiments, t is selected from 2. In some embodiments, X 8 In some embodiments, Ring A is selected from In some embodiments, Ring A is selected from In some embodiments, Ring A is selected from

[0124] In some embodiments, Ring A is selected from where X t is selected from NH or O. In some embodiments, ring A is selected from In some embodiments, Ring A is selected from In some embodiments, Ring A is selected from

[0125] In other embodiments, Ring A is selected from 3-8 membered heterocycloalkyl or 3-8 membered heterocycloalkenyl.

[0126] In other embodiments, Ring A is selected from 3-6 membered heterocycloalkyl or 3-6 membered heterocycloalkenyl. In other embodiments, Ring A is selected from 5-6 membered heterocycloalkyl.

[0127] In some embodiments, the heterocycloalkyl or heterocycloalkenyl group in ring A has a heteroatom selected from nitrogen, oxygen, sulfur, phosphorus, or boron. In some embodiments, the heterocycloalkyl or heterocycloalkenyl group in ring A has a heteroatom selected from nitrogen, oxygen, or sulfur. In some embodiments, the heterocycloalkyl or heterocycloalkenyl group in ring A has a heteroatom selected from 1, 2, 3, 4, or 5. In some embodiments, the heterocycloalkyl or heterocycloalkenyl group in ring A has a heteroatom selected from 1, 2, or 3.

[0128] In some embodiments, the heterocycloalkyl or heterocycloalkenyl group in ring A contains no more than 2 nitrogen atoms among the heteroatoms constituting ring A.

[0129] In some embodiments, the heterocycloalkyl or heterocycloalkenyl in ring A has only one N atom or only two N atoms among the heteroatoms constituting ring A.

[0130] In some embodiments, the heterocycloalkyl or heterocycloalkenyl in ring A has only one N atom and one S atom among the heteroatoms constituting ring A.

[0131] In other embodiments, Ring A is selected from pyrrolidinyl, thiazolidinyl, imidazolidinyl, piperidinyl, or piperazinyl.

[0132] In other embodiments, Ring A is selected from

[0133] In some embodiments, the structural unit Selected from In some embodiments, the structural unit Selected from

[0134] In other embodiments, the structural unit Selected from In some embodiments, Ring A is selected from

[0135] The structural unit or, or Optionally, one, two or three R 2 replace.

[0136] In some embodiments, Ring A, the building block Selected from or In some embodiments, Ring A, the building block Selected from

[0137] In other embodiments, the structural unit Selected from

[0138] In some embodiments, the structural unit Selected from In some embodiments, the structural unit Selected from

[0139] In another aspect, the present disclosure provides a compound of Formula IA, IA-1, IA-2, or IA-3, or a pharmaceutically acceptable salt thereof,

[0140] Among them, X 1 、X 2 、X 3 、X 4 、X 5 、R 1 、R 2 、R a , m and n are as defined in this disclosure;

[0141] q is selected from 0, 1, 2 or 3;

[0142] X a and X c are independently selected from CH or N. In some embodiments, X a and X c Selected from CH.

[0143] In some embodiments, q is selected from 0, 1, or 2. In some embodiments, q is selected from 0 or 1. In some embodiments, q is selected from 0.

[0144] In another aspect, the present disclosure provides a compound of Formula II, II-1, II-2 or II-3, or a pharmaceutically acceptable salt thereof,

[0145] Among them, ring A, X 1 、X 2 、X 3 、X 4 、X 5 、R 1 、R 2 , m and n are defined as described in the present disclosure.

[0146] In another aspect, the present disclosure provides a compound of Formula III, IV, IIIA or IVA, or a pharmaceutically acceptable salt thereof,

[0147] Among them, X a 、X c 、R 1 、R a , q and m are as defined in this disclosure;

[0148] Ring B is selected from 3-10 membered heterocycloalkyl or 3-10 membered heterocycloalkenyl;

[0149] R 2a The definition of R in this disclosure 2 As stated;

[0150] Or, each R 2a are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 alkyl)2N-、HOC(O)-、C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1- 6-alkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl;

[0151] p is selected from 0, 1, 2 or 3;

[0152] T is selected from S═O or C.

[0153] In some embodiments, X a and X c In some embodiments, X a and X c Selected from CH.

[0154] In some embodiments, Ring B is selected from 3-8 membered heterocycloalkyl or 3-8 membered heterocycloalkenyl.

[0155] In some embodiments, Ring B is selected from 3-6 membered heterocycloalkyl or 3-6 membered heterocycloalkenyl.

[0156] In some embodiments, Ring B is selected from 3-10 membered heterocycloalkyl.

[0157] In some embodiments, Ring B is selected from 4-10 membered heterocycloalkyl.

[0158] In some embodiments, Ring B is selected from 4-8 or 10-membered heterocycloalkyl.

[0159] In some embodiments, Ring B is selected from 4-6 membered monocyclic heterocycloalkyl, 7-8 membered, or 10 membered spiroheterocycloalkyl.

[0160] In some embodiments, Ring B is selected from 4-8 membered heterocycloalkyl.

[0161] In some embodiments, Ring B is selected from 4-6 membered heterocycloalkyl.

[0162] In some embodiments, Ring B is selected from 5-6 membered heterocycloalkyl.

[0163] In some embodiments, Ring B is selected from pyrrolidinyl, thiazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, diazaspirodecanyl, monooxa-azaspirooctanyl, azetidinyl, monoazaspiroheptanyl, or oxazolidinyl.

[0164] In some embodiments, Ring B is selected from oxazolidinyl, pyrrolidinyl, thiazolidinyl, imidazolidinyl, piperidinyl, or piperazinyl.

[0165] In some embodiments, Ring B is selected from pyrrolidinyl, thiazolidinyl, imidazolidinyl, piperidinyl, or piperazinyl.

[0166] In some embodiments, the structural unit Selected from In some embodiments, the structural unit Selected from In some embodiments, the structural unit Selected from In some embodiments, the structural unit Selected from In some embodiments, the structural unit Selected from

[0167] In some embodiments, the structural unit Selected from

[0168] In some embodiments, the structural unit As structural unit Definition of .

[0169] In some embodiments, the structural unit Selected from

[0170] In some embodiments, each R 2a The definition of R in this disclosure 2 Definition of the group (ie, the same as the R 2 same).

[0171] In some embodiments, each R2a are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1- 6 alkyl) 2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1- 6-alkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 aryl or 5-12 membered heteroaryl.

[0172] In some embodiments, each R 2a are independently selected from CN, halogen, OH, NH2, C 1-4 Alkyl, C 1-4 Alkyl O-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C1-4 Alkyl C(O)O-, C 1-4 Alkyl NHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl) 2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-4 Alkyl, C 1-4 Alkyl O-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl NH-, -COOH, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-.

[0173] In some embodiments, each R 2a are independently selected from CN, halogen, OH, NH2, C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, C 1-3 Alkyl OC (O) - or 5-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, C 1-3 Alkyl OC (O) - or 5-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl, -COOH, or C 1-3 AlkylOC(O)-.

[0174] In some embodiments, each R 2a They are independently selected from CN, halogen, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl, and the methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen (such as F or Cl), OH, NH2, methyl, -COOH, or CH3OC(O)-.

[0175] In some embodiments, each R 2aThey are independently selected from CN, halogen, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl, and the methyl, ethyl, CH3CH2NH- or 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: halogen (such as F or Cl), OH, NH2, methyl, -COOH, or CH3OC(O)-.

[0176] In some embodiments, each R 2a are independently selected from halogen (such as F or Cl), OH, NH2, -CH3, -CH2OH, -CH2F, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2C(O)OCH3, -CH2C(O)OH, -OCH3, -NHCH3, -NHCH2CH2NH2, -C(O)OCH3, -C(O)OCH2CH3 or

[0177] In other embodiments, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl)2N-.

[0178] In other embodiments, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1- 6-alkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl) 2NS(O)-, C 1-6 Alkyl NHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 alkyl)2NS(O)2-、C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl)2N-.

[0179] In other embodiments, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1-3 Alkyl)2N-.

[0180] In other embodiments, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl) 2N-, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 alkyl)2N- is optionally substituted with one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1-3 Alkyl)2N-.

[0181] In some embodiments, R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4Alkyl S-, -SF5, C 1-4 Alkyl NH- or (C 1-4 Alkyl) 2N-, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH- or (C 1-4 alkyl)2N- is optionally substituted with one or more of the following groups: CN, halogen, OH or NH2. In other embodiments, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl or C 2-4 Alkynyl-, the C 1-4 Alkyl, C 2-4 Alkenyl or C 2-4 Alkynyl- is optionally substituted with one or more of the following: CN, halogen, OH, or NH2.

[0182] In other embodiments, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-3 Alkyl, C 2-3 Alkenyl or C 2-3 Alkynyl-, the C 1-3 Alkyl, C 2-3 Alkenyl or C 2-3 Alkynyl- is optionally substituted with one or more of the following: CN, halogen, OH, or NH2.

[0183] In other embodiments, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more groups selected from CN, halogen, OH or NH2.

[0184] In other embodiments, each R 2a are independently selected from halogen, =O, OH or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more groups selected from halogen, OH or NH2.

[0185] In other embodiments, each R 2a are independently selected from F, =O, OH or C optionally substituted with one or more OH or F 1-3 alkyl.

[0186] In other embodiments, each R 2a Each is independently selected from F, =O, OH, -CH3, -CH(OH)CH3, -CH2OH or -CH2F.

[0187] In other embodiments, each R 2a are independently selected from =O, OH or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more groups selected from OH or NH2.

[0188] In other embodiments, each R 2a are independently selected from =O, OH or C optionally substituted with one or more OH 1-3 Alkyl (e.g. -C 1-3 alkyl-OH).

[0189] In other embodiments, each R 2a Each is independently selected from ═O, OH, —CH 3 or —CH 2 OH.

[0190] In some embodiments, p is selected from 0, 1 or 2.

[0191] In another aspect, the present disclosure provides a compound of Formula V, VI or VII, or a pharmaceutically acceptable salt thereof,

[0192] Among them, X a 、X c 、R 1 、R 2a , p and m are as defined in this disclosure; X t is selected from CH2, NH or O.

[0193] In some embodiments, m is selected from 1, R 1 Replace in X 3 In some embodiments, X 3 is selected from CH, m is selected from 1, R 1 Substitution occurs at X 3 Location.

[0194] In some embodiments, R 1 Substitution occurs at the para position of the connected benzene ring, forming the following structural unit

[0195] In some embodiments, X 1 、X 2 、X 3 、X 4 and X 5are independently selected from CH, and X is selected from O.

[0196] In some embodiments, heterocycloalkyl and heterocycloalkenyl each independently contain 1, 2, or 3 heteroatoms independently selected from N, O, and S. In some embodiments, heterocycloalkyl and heterocycloalkenyl each independently contain 1 or 2 heteroatoms independently selected from N and O.

[0197] In some embodiments, the heteroaryl group contains 1, 2, or 3 heteroatoms independently selected from N, O, and S.

[0198] In some embodiments, the heterocyclyl contains 1, 2, or 3 heteroatoms independently selected from N, O, and S. In some embodiments, the heterocyclyl contains 1 or 2 heteroatoms independently selected from N and O.

[0199] In some embodiments, the halo is selected from fluoro, chloro, or bromo. In some embodiments, the halo is selected from fluoro or chloro. In some embodiments, the halo is selected from fluoro.

[0200] In some embodiments, the C 1-10 Selected from C 1-9 、C 1-8 、C 1-7 、C 1-6 、C 1-4 、C 1-3 , or C 1-2 In some embodiments, C 1- 6 from C 1-4 、C 1-3 , or C 1-2 In some embodiments, the C 1-4 is selected from C4, C3, C2, or C1. In some embodiments, the C 1-3 Selected from C3, C2, or C1.

[0201] In some embodiments, the C 2-10 Selected from C 2-8 、C 2-6 、C 2-5 、C 2-4 、C 2-3 In some embodiments, the C 2-6 Selected from C 2- 4. or C 2-3 In some embodiments, the C 2-4 Selected from C4, C3, or C2.

[0202] In some embodiments, the C 3-6 Selected from C 3-5 、C 3-4 、C4-6 、C 4-5 , or C 5-6 In some embodiments, the C 6-10 Selected from C 6-9 、C 6-8 、C 6-7 、C 7-10 、C 7-9 、C 7-8 、C 8-10 、C 8-9 , or C 9-10 In some embodiments, the C 3-10 Selected from C 3-9 、C 3-8 、C 3- 7. C 3-6 、C 3-5 、C 3-4 、C 4-10 、C 4-9 、C 4-8 、C 4-7 、C 4-6 、C 4-5 、C 5-10 、C 5-9 、C 5-8 、C 5-7 、C 5-6 、C 6-10 、C 6-9 、C 6-8 、C 6- 7. C 7-12 、C 7-10 、C 7-9 、C 7-8 、C 8-12 、C 8-10 、C 8-9 、C 9-12 , or C 9-10 In some embodiments, the C 3-15 Selected from C 3-12 or C 3- 10 In some embodiments, the C 3-12 Selected from C 3-10 In some embodiments, the C 6-12 Selected from C 6-10 .

[0203] In some embodiments, the 3-6 yuan is selected from 3-5 yuan, 3-4 yuan, 4-6 yuan, 4-5 yuan, or 5-6 yuan. In some embodiments, the 5-10 yuan is selected from 5-8 yuan, 5-7 yuan, 5-6 yuan, 6-10 yuan, 6-9 yuan, 6-8 yuan, 6-7 yuan, 7-10 yuan, 7-9 yuan, 7-8 yuan, 8-10 yuan, 8-9 yuan, and 9-10 yuan. In some embodiments, the 3-10 yuan is selected from 3-9 yuan, 3-8 yuan, 3-7 yuan, 3-6 yuan, 3-5 yuan, 3-4 yuan, 4-10 yuan, 4-9 yuan, 4-8 yuan, 4-7 yuan, 4-6 yuan, 4-5 yuan, 5-10 yuan, 5-9 yuan, 5-8 yuan, 5-7 yuan, 5-6 yuan, 6-10 yuan, 6-9 yuan, 6-8 yuan, 6-7 yuan, 7-10 yuan, 7-9 yuan, 7-8 yuan, 8-10 yuan, 8-9 yuan, 9-10 yuan. In some embodiments, the 3-15 yuan is selected from 3-12 yuan or 3-10 yuan. In some embodiments, the 3-12 yuan is selected from 3-10 yuan. In some embodiments, the 5-12 yuan is selected from 5-10 yuan.

[0204] In some embodiments, the compounds of the present disclosure are not selected from the following compounds:

[0205] In some embodiments, the compounds of the present disclosure are not selected from the following compounds:

[0206] In some embodiments, the compounds of the present disclosure are not selected from the following compounds:

[0207] In another aspect, the present disclosure relates to the following compounds, or pharmaceutically acceptable salts thereof:

[0208] In some embodiments, the present disclosure discloses a compound having an asymmetric carbon atom, wherein the compound comprises a first-eluting compound or a last-eluting compound after liquid phase separation. In some specific embodiments, the mobile phase for liquid phase separation is the mobile phase in the examples of the present disclosure.

[0209] On the other hand, the present disclosure relates to a pharmaceutical composition, which contains the above-mentioned compound of the present disclosure or a pharmaceutically acceptable salt thereof, and the pharmaceutical composition of the present disclosure further includes a pharmaceutically acceptable excipient.

[0210] In another aspect, the present disclosure relates to the use of the above-mentioned compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for preventing or treating a disease (eg, a disease associated with TEAD).

[0211] In another aspect, the present disclosure relates to a method for treating or preventing a disease (e.g., a disease associated with TEAD), comprising administering a therapeutically effective amount of the above-mentioned compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to a mammal, preferably a human, in need of such treatment.

[0212] In another aspect, the present disclosure relates to the use of the above-mentioned compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in preventing or treating a disease (eg, a disease associated with TEAD).

[0213] In another aspect, the present disclosure relates to the above-mentioned compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for preventing or treating a disease (eg, a disease associated with TEAD).

[0214] In some specific embodiments, the disease (eg, a disease associated with TEAD) is selected from cancer; in some more specific embodiments, the disease (eg, a disease associated with TEAD) is selected from mesothelioma and lung cancer.

[0215] In some aspects, the present disclosure comprises the above-defined variables and embodiments thereof, and any combination thereof.

[0216] Technical Effects

[0217] The disclosed compounds have excellent in vitro protein binding activity, specifically binding to TEAD1, TEAD2, TEAD3, or TEAD4 proteins. They exhibit proliferation inhibitory activity against NCI-H226 or NCI-H2052 cells, but have essentially no proliferation inhibitory activity against NCI-H2452 cells. They exhibit excellent selectivity for NCI-H226 or NCI-H2052 cells relative to NCI-H2452 cells. They are metabolically stable in vitro and exhibit good pharmacokinetic properties and efficacy in vivo.

[0218] definition

[0219] Unless otherwise indicated, the following terms used in this disclosure have the following meanings. A particular term should not be construed as undefined or unclear unless specifically defined, but rather should be understood according to its ordinary meaning in the art. When a trade name appears herein, it is intended to refer to the corresponding commercial product or its active ingredient.

[0220] In some embodiments, the "one or more" is selected from one, two, three, four, five or six. In some embodiments, the "one or more" is selected from one, two, or three. In some embodiments, the "one or more" is selected from one, or two. The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are replaced, and oxo does not occur on aromatic groups.

[0221] The term "optionally" or "optionally" means that the event or situation described subsequently may or may not occur, and the description includes both the occurrence of the event or situation and the non-occurrence of the event or situation. For example, an ethyl group is "optionally" substituted with a halogen, meaning that the ethyl group may be unsubstituted (CH2CH3), monosubstituted (such as CH2CH2F), polysubstituted (such as CHFCH2F, CH2CHF2, etc.), or fully substituted (CF2CF3). It will be understood by those skilled in the art that for any group containing one or more substituents, no substitution or substitution pattern that is sterically impossible and / or cannot be synthesized will be introduced. For example, the C 1-6 Alkyl (C 1-4 alkyl) and the like are optionally substituted by one or more of the following groups: CN, halogen, OH or NH2, which may form, for example, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-NH2 and other groups.

[0222] The “substituents” mentioned herein include, but are not limited to, the terms “alkyl”, “alkoxy”, “cycloalkyl”, “heterocycloalkyl”, “heteroaryl”, “alkenyl”, “alkynyl”, “cycloalkenyl”, “heterocycloalkenyl”, “heteroaromatic ring”, etc., and corresponding non-limiting or exemplary groups, wherein some non-limiting examples of the “substituents” include protium, deuterium, tritium, -OH, -SF5, -SH, halogen, -NH2, nitro, nitroso, -CN, azide, sulfoxide, sulfone, sulfone, sulfonamide, etc. , carboxyl, carboxaldehyde group, imine group, alkyl, halo-alkyl, cycloalkyl, halo-cycloalkyl, alkenyl, halo-alkenyl, cycloalkenyl, halo-cycloalkenyl, alkynyl, halo-alkynyl, cycloalkynyl, halo-cycloalkynyl, heteroalkyl, halo-heteroalkyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, aralkyl, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroaralkyl, heteroarylalkoxy, heteroarylalkylthio, heterocyclyl, heterocyclyloxy, heterocyclylthio, hetero Cyclic alkyl, heterocyclyl alkoxy, heterocyclyl alkylthio, acyl, acyloxy, carbamate group, amide group, urea group, epoxy group and ester group, etc., which are optionally substituted by one or more substituents selected from the following: oxo, hydroxyl, amino, nitro, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, carboxyl, -C (O) O-alkyl, -OC (O) -alkyl, -C (O) NH2, -C ( -C(O)NH-alkyl, -C(O)N(alkyl), -NHC(O)-alkyl, -C(O)-alkyl, -S(O)-alkyl, -S(O)2-alkyl, -S(O)2NH2, -S(O)2NH-alkyl, -S(O)2N(alkyl), cycloalkyl, cycloalkylalkyl, cycloalkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkyl, heterocyclyloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, aryl, arylalkyl, or aryloxy.

[0223] In some embodiments herein, the “substituent” is selected from deuterium, tritium, -SF5, hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azide, sulfoxide, sulfone, sulfone, sulfonamide, carboxyl, aldehyde, imine, C 1-12 Alkyl, halo-C 1-12 Alkyl, 3-12 membered cycloalkyl, halogenated 3-12 membered cycloalkyl, C 2-12 Alkenyl, halo-C 2-12 Alkenyl, 3-12 membered cycloalkenyl, halogenated 3-12 membered cycloalkenyl, C 2- 12 Alkynyl, halo-C 2-12 Alkynyl, 8-12 membered cycloalkynyl, halogenated 8-12 membered cycloalkynyl, C1-12 Heteroalkyl, halo-C 1-12 Heteroalkyl, C 1-12 Alkoxy, C 1-12 Alkylthio, 6-10 membered aryl, 6-10 membered aryloxy, 6-10 membered arylthio, 6-10 membered arylC 1-12 Alkylene, 6-10 membered aryl C 1-12 Alkoxy, 6-10 membered aryl C 1-12 alkylthio, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, 5-10 membered heteroarylthio, 5-10 membered heteroarylalkylene, 5-10 membered heteroarylalkoxy, 5-10 membered heteroarylalkylthio, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, 3-12 membered heterocyclylthio, 3-12 membered heterocyclylC 1-12 Alkylene, 3-12 membered heterocyclic group C 1-12 Alkoxy, 3-12 membered heterocyclic group C 1-12 Alkylthio, C 1-12 Acyl, C 1-12 Acyloxy, carbamate group, C 1-12 Amide group, urea group, epoxy group, C 2-12 Ester group and oxo, said substituent being optionally substituted by one or more substituents selected from the group consisting of oxo, hydroxy, amino, nitro, halogen, cyano, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, C 1-12 Alkylamino, di-C 1-12 Alkylamino, halogenated C 1-12 Alkylamino, halogenated di-C 1-12 Alkylamino, carboxyl, -C(O)OC 1-12 Alkyl, -OC(O)-C 1-12 Alkyl, -C(O)NH2, -C(O)NH-C 1-12 Alkyl, -C(O)N(C 1-12 Alkyl)2, -NHC(O)-C 1-12 Alkyl, -C(O)-C 1-12 Alkyl, -S(O)-C 1-12 Alkyl, -S(O)2-C 1-12 Alkyl, -S(O)2NH2, -S(O)2NH-C 1- 12 Alkyl, -S(O)2N(C 1-12 alkyl) 2, 3-12 membered cycloalkyl, 3-12 membered cycloalkyl C 1-12 Alkylene, 3-12 membered cycloalkyloxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group C1-12 Alkylene, 3-12 membered heterocyclyloxy, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkylC 1-12 Alkylene, 3-12 membered heterocycloalkyloxy, 5-10 membered heteroaryl, 5-10 membered heteroarylC 1-12 Alkylene, 5-10 membered heteroaryloxy, 6-10 membered aryl, 6-10 membered arylC 1-12 an alkylene group or a 6- to 10-membered aryloxy group.

[0224] In this article, C m-n , means that the moiety has an integer number of carbon atoms in a given range. For example, "C 1-12 " means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, 10 carbon atoms, 11 carbon atoms or 12 carbon atoms. For example, "C 1-6 " means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms. For example, "C 1-3 " means that the group may have 1 carbon atom, 2 carbon atoms, or 3 carbon atoms.

[0225] In this article, "mn yuan" refers to an integer number in a given range. For example, "3-12 yuan" means 3 yuan, 4 yuan, 5 yuan, 6 yuan, 7 yuan, 8 yuan, 9 yuan, 10 yuan, 11 yuan, or 12 yuan. For example, "5-10 yuan" means 5 yuan, 6 yuan, 7 yuan, 8 yuan, 9 yuan, or 10 yuan. For example, "3-6 yuan" means 3 yuan, 4 yuan, 5 yuan, or 6 yuan.

[0226] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. For example, if a group contains two R's, each R has an independent option.

[0227] When a bond crosses two atoms in a ring (including a monocyclic, fused, or spirocyclic ring), the bond may be bonded to any atom in the ring (including a monocyclic, fused, or spirocyclic ring).

[0228] The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.

[0229] The term "hydroxy" refers to an -OH group.

[0230] The term "amino" refers to a -NH2 group.

[0231] In each group containing a "heteroatom" in the present disclosure, the "heteroatom" includes an atom of any element other than carbon or hydrogen. Preferred heteroatoms are boron, nitrogen, oxygen, sulfur, silicon and phosphorus, wherein the nitrogen atom is optionally quaternized or oxidized to N(O), the sulfur atom is optionally oxidized to S(O) or S(O)2, and the phosphorus atom is optionally oxidized to P(O) or P(O)2.

[0232] The term "alkyl" refers to a group of the formula C n H 2n+1 The alkyl group may be straight chain or branched. For example, the term "C 1-6 The term "alkyl" refers to an alkyl group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc.). Similarly, the alkyl portion (i.e., alkyl) of alkoxy, alkylamino, dialkylamino, alkylsulfonyl, and alkylthio has the same definition as above.

[0233] The term "alkoxy" refers to an -O-alkyl group.

[0234] The term "alkenyl" refers to a linear or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one double bond. Non-limiting examples of alkenyl include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, 1,3-butadienyl, and the like.

[0235] The term "alkynyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one triple bond. Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH), 1-propynyl (-C≡C-CH3), 2-propynyl (-CH2-C≡CH), 1,3-butadiynyl (-C≡C≡CH), and the like.

[0236] The term "cycloalkenyl" refers to an incompletely saturated and non-aromatic carbocyclic ring that can exist as a monocycle, a bicyclic bridged ring or a spirocycle. Unless otherwise indicated, the carbocyclic ring is typically 3 to 20 rings, 3 to 15 rings or 3 to 10 rings (such as 4 to 8 rings). Unless otherwise indicated, the carbocyclic ring is typically 4 to 10 rings (such as 5 to 8 rings, specifically such as 5, 6, 7, 8, 9 or 10 rings). The limiting examples of cycloalkenyl include but are not limited to cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl etc.

[0237] The term "cycloalkyl" refers to a fully saturated carbocyclic ring that can exist as a monocycle, a bridged ring or a spirocycle. Unless otherwise indicated, the carbocyclic ring is typically 3 to 20 rings, 3 to 15 rings or 3 to 10 rings (e.g., 5 to 8 rings, specifically 5, 6, 7, 8, 9 or 10 rings). Non-limiting examples of cycloalkyl include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo [2.2.1] heptyl), bicyclo [2.2.2] octyl, adamantyl etc.

[0238] The term "heterocycloalkyl" refers to a cyclic group that is fully saturated and can exist as a monocyclic, bridged or spirocyclic ring. Unless otherwise indicated, the heterocycle is typically a 3 to 20-membered ring, a 3 to 15-membered ring, a 3 to 7-membered ring, a 3 to 6-membered ring or a 3 to 5-membered ring containing 1 to 6 or 1 to 3 heteroatoms independently selected from boron, nitrogen, oxygen, sulfur, silicon and / or phosphorus (preferably sulfur, oxygen and / or nitrogen heteroatoms, preferably 1, 2 or 3 heteroatoms). Examples of 3-membered heterocycloalkyl groups include, but are not limited to, oxirane, thioethane, and aziridine groups; non-limiting examples of 4-membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, and thietanyl groups; examples of 5-membered heterocycloalkyl groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, imidazolidinyl, and tetrahydropyrazolyl groups; examples of 6-membered heterocycloalkyl groups include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, piperazinyl, 1,4-thioxanyl, 1,4-dioxanyl, thiomorpholinyl, 1,3-dithianyl, and 1,4-dithianyl groups; examples of 7-membered heterocycloalkyl groups include, but are not limited to, azepanyl, oxetanyl, and thiepanyl groups. Preferably, the heterocycloalkyl group is a monocyclic group having 5 or 6 ring atoms.

[0239] The term "heterocycloalkenyl" includes cycloalkenyl groups in which one or more carbon atoms, for example up to 3 carbon atoms, or up to 2 carbon atoms, or 1 carbon atom, are independently replaced by B, O, S, S(O), S(O)2, N, Si, P, or P(O), provided that at least one cycloalkenyl carbon-carbon double bond is retained. The cyclic group, which may exist as a monocyclic, bridged, or spirocyclic ring, may be a 3- to 20-membered ring, a 3- to 15-membered ring, or a 3- to 13-membered ring (e.g., a 5- to 13-membered ring, a 5- to 8-membered ring, specifically a 5-, 6-, 7-, 8-, 9-, 10-, or 11-membered ring).

[0240] The term "heterocyclic radical" refers to a non-aromatic ring that is fully saturated or partially undersaturated (but not fully unsaturated heteroaromatic) and can exist as a monocycle, a bridged ring or a spirocycle. Unless otherwise indicated, the heterocycle is typically 3 to 20 yuan (or 3 to 17 yuan, or 3 to 13 yuan, or 3 to 7 yuan, specifically such as 4 yuan, 5 yuan, 6 yuan, 7 yuan, 8 yuan, 9 yuan or 10 yuan ring) ring containing 1 to 3 heteroatoms (preferably 1, 2 or 3 heteroatoms) independently selected from boron, sulphur, oxygen and / or nitrogen. The limiting examples of heterocyclic radicals include but are not limited to oxiranyl, tetrahydrofuranyl, dihydrofuranyl, pyrrolidinyl, N-methylpyrrolidinyl, dihydropyrrolyl, piperidyl, piperazinyl, pyrazolidinyl, 4H-pyranyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl etc. The heterocyclyl group can be, for example, a heterocycloalkenyl group, a heterocycloalkyl group, or a benzoheterocycloalkenyl group (which is not a fully saturated heteroaromatic group).

[0241] The term "aryl" refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated π electron system. For example, an aryl group can have 6-20 carbon atoms, 6-14 carbon atoms, or 6-12 carbon atoms, or 6-10 (e.g., 6, 7, 8, 9, or 10) carbon atoms. Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, and 1,2,3,4-tetrahydronaphthalene.

[0242] The term "heteroaryl" refers to a monocyclic or fused polycyclic ring system containing at least one ring atom selected from nitrogen, oxygen, S, with the remaining ring atoms being C and having at least one aromatic ring. Preferred heteroaryl groups have single 4 to 8 rings, especially 5 to 8 (e.g., 5, 6, 7, or 8) rings, or multiple fused rings containing 6 to 20, or 6 to 14, especially 6 to 10 (e.g., 6, 7, 8, 9, or 10) ring atoms. Non-limiting examples of heteroaryl groups include, but are not limited to, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, triazolyl, triazinyl, benzofuranyl, benzothienyl, indolyl, isoindolyl, etc.

[0243] The term "treating" means administering a compound or formulation of the present disclosure to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:

[0244] (i) inhibiting a disease or disease state, i.e., arresting its development;

[0245] (ii) ameliorating the disease or condition, i.e., causing regression of the disease or condition.

[0246] The term "prevention" means administering a compound or formulation of the present disclosure to prevent a disease or one or more symptoms associated with the disease, including preventing the disease or disease state from occurring in a mammal, particularly when such mammal is susceptible to the disease state but has not yet been diagnosed as having the disease state.

[0247] The term "therapeutically effective amount" means an amount of a compound of the present disclosure that (i) treats or prevents a specific disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a specific disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition, or disorder described herein. The amount of a compound of the present disclosure that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by one skilled in the art based on their own knowledge and this disclosure.

[0248] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0249] As the pharmaceutically acceptable salt, for example, metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids and the like can be mentioned.

[0250] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present disclosure or their salts and a pharmaceutically acceptable excipient. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present disclosure to an organism.

[0251] The term "pharmaceutically acceptable excipient" refers to an excipient that is non-irritating to organisms and does not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art and include, for example, carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.

[0252] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be understood as having an open and non-exclusive meaning, ie, "including but not limited to".

[0253] The compounds and intermediates of the present disclosure may also exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. A specific example of a proton tautomer is the imidazole moiety, in which a proton can migrate between two ring nitrogens. Valence tautomers include interconversions by reorganization of some bonding electrons.

[0254] The present disclosure also includes isotopically labeled compounds of the present disclosure that are identical to those described herein, but where one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.

[0255] Certain isotopically labeled compounds of the present disclosure (e.g., 3 H and 14 C-labeled) can be used in compound and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. Positron emitting isotopes, such as 15 O. 13 N. 11 C and 18 F can be used in positron emission tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the disclosure can generally be prepared by following procedures analogous to those disclosed in the Schemes and / or Examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0256] In addition, the use of heavier isotopes such as deuterium (i.e. 2H)) substitution may provide certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and may therefore be preferred in certain circumstances, wherein deuterium substitution may be partial or complete, with partial deuterium substitution meaning that at least one hydrogen is replaced by at least one deuterium. For example, it is understood that compounds wherein one or more hydrogen atoms in a compound of Formula 1C of the present disclosure are replaced by deuterium atoms are still within the scope of the compounds of Formula 1C of the present disclosure.

[0257] The compounds of the present disclosure may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. The compounds of the present disclosure containing asymmetric carbon atoms can be isolated in optically pure forms or racemic forms. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.

[0258] The pharmaceutical compositions of the present disclosure can be prepared by combining the compounds of the present disclosure with suitable pharmaceutically acceptable excipients. Therefore, the compounds of the present disclosure may contain pharmaceutically acceptable excipients.

[0259] The pharmaceutical composition of the present disclosure can be manufactured by methods well known in the art, such as conventional mixing methods, dissolving methods, granulating methods, making dragees, grinding methods, emulsifying methods, freeze-drying methods, and the like.

[0260] In all methods of administration described herein, the compounds of formula I are administered at a dosage of 0.001 to 2000 mg / kg body weight per day in single or divided doses.

[0261] The compounds disclosed herein can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include, but are not limited to, the examples disclosed herein.

[0262] The chemical reactions of the embodiments of the present disclosure are carried out in a suitable solvent that is compatible with the chemical transformations of the present disclosure and the reagents and materials required. In order to obtain the compounds of the present disclosure, it is sometimes necessary for those skilled in the art to modify or select synthetic steps or reaction schemes based on existing embodiments.

[0263] An important consideration in synthetic route planning in this field is the selection of appropriate protecting groups for reactive functional groups (such as the amino groups in the present disclosure). For example, reference can be made to Greene's Protective Groups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley & Sons, Inc.

[0264] The compounds disclosed herein can be prepared by the following routes in combination with techniques known in the art:

[0265] Among them, ring A, X 1 、X 2 、X 3 、X 4 、X 5 , X, R 1 、R 2 、X a 、X b 、X c 、X d 、X e 、X f , m and n are as defined in the present disclosure, Z 1 or Z 2 are each independently halogen.

[0266] In some embodiments, X is selected from O.

[0267] In some embodiments, Z 1 is selected from fluorine; Z 2 Selected from bromine; R 5 Selected from C 1-6 Alkyl (eg, methyl, ethyl, or propyl).

[0268] This disclosure uses the following abbreviations:

[0269] DMF stands for dimethylformamide; DMSO stands for dimethyl sulfoxide; EA stands for ethyl acetate; PE stands for petroleum ether; MeOH stands for methanol; DCM stands for dichloromethane; THF stands for tetrahydrofuran; NMP stands for tert-butyloxycarbonyl; Boc stands for tert-butyloxycarbonyl; Bn stands for benzyl; Xant-Phos stands for 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; Pd2(dba)3 stands for tris(dibenzylideneacetone)dipalladium; EDCI stands for 1-(3-dimethylamino)propyl The invention further comprises the following: (i) 1,2-dimethylaminopyridine (DMAP), (ii) 2,4-dimethylaminopyridine (DMAP), (iii) 2,4-dimethyltetrahydrofuran (2-MeTHF), (iv) N,N-diisopropylethylamine (DIPEA), (v) HATU, (v) N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (UIP), (v) LDA, (v) lithium diisopropylamide (LIDI), (v) TBAF, (v) tetrabutylammonium fluoride (TBAF), (v) Cbz, (v) benzyloxycarbonyl (BZ), (v) Pd(OAc)2, (v) palladium acetate (PA), and (v) Me, which represents a methyl group. DETAILED DESCRIPTION

[0270] For the sake of clarity, the present disclosure is further illustrated with examples, but the examples do not limit the scope of the present disclosure. All reagents used in the present disclosure are commercially available and can be used without further purification.

[0271] The single crystal growth method was used to confirm the R or S configuration of some isomers of the following examples.

[0272] Example 1

[0273] Step A: Compound 1-1 (1.00 g), 1-fluoro-4-trifluoromethyl-benzene (3.68 g), cesium carbonate (7.30 g), and DMF (10 mL) were added sequentially to a microwave tube and heated to 120°C for 2 h. After the reaction, water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated sodium chloride water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain compound 1-2 (1.45 g).

[0274] 1 H NMR (500MHz, DMSO-d6) δ8.35(d,J=2.0Hz,1H),7.90(d,J=9.0Hz,1H),7.85(d,J=8.4Hz,1H),7.74(d,J=8 .7Hz,2H),7.68(dd,J=9.0,2.0Hz,1H),7.63-7.60(m,1H),7.27(d,J=7.6Hz,1H),7.17(d,J=8.6Hz,2H).

[0275] Step B: Compound 1-2 (250 mg), Pd2(dba)3 (12.5 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (23.5 mg), cesium carbonate (665 mg), 4-hydroxy-2-pyrrolidone (82.5 mg), and 1,4-dioxane (10 mL) were added sequentially to an eggplant-shaped flask and refluxed at 110°C for 5 hours under N2 protection. After the reaction, water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated sodium chloride water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain compound 1 (100 mg).

[0276] 1 H NMR (500MHz, DMSO-d6) δ8.11(d,J=2.1Hz,1H),8.08(dd,J=9.2,2.2Hz,1H),7.92(d,J=9. 2Hz,1H),7.82(d,J=8.35Hz,1H),7.73(d,J=8.70Hz,2H),7.54(t,J=7.75Hz,1H),7.19-7. 10(m,3H),5.40(d,J=3.90Hz,1H),4.48-4.41(m,1H),4.21-4.15(m,1H),3.74(d,J=10.4 5Hz,1H),2.89(dd,J=17.05,6.15Hz,1H),2.37(dd,J=17.05,1.65Hz,1H).MS(ESI+,[M+H] + )m / z:388.04.

[0277] Step C: Compound 1 (260 mg) was subjected to chiral separation (YMC high pressure preparative chromatography: CHIRALART Cellulose-SC column, ethanol / n-hexane). The first eluting peak was Example 1_A (112 mg), and the second eluting peak was Example 1_B (120 mg).

[0278] Example 1_A: 1H NMR(500MHz,DMSO-d6)δ8.11(d,J=2.1Hz,1H),8.10-8.07(m,1H),7.92(d,J= 9.2Hz,1H),7.82(d,J=8.3Hz,1H),7.73(d,J=8.5Hz,2H),7.53(t,J=7.9Hz,1H ),7.17-7.11(m,3H),5.40(d,J=3.9Hz,1H),4.47-4.43(m,1H),4.22-4.14(m, 1H),3.77-3.70(m,1H),2.94-2.85(m,1H),2.39-2.33(m,1H).MS(ESI+,[M+H] + )m / z:388.17.

[0279] Example 1_B: 1 H NMR(500MHz,DMSO-d6)δ8.11(d,J=2.2Hz,1H),8.10-8.05(m,1H),7.92(d,J= 9.1Hz,1H),7.82(d,J=8.3Hz,1H),7.73(d,J=8.5Hz,2H),7.53(t,J=7.9Hz,1H ),7.17-7.11(m,3H),5.40(d,J=3.9Hz,1H),4.47-4.44(m,1H),4.22-4.15(m, 1H),3.77-3.72(m,1H),2.92-2.86(m,1H),2.39-2.32(m,1H).MS(ESI+,[M+H] + )m / z:388.17.

[0280] Example 2 (2_A and 2_B)

[0281] Referring to the synthesis of Example 1, in step B, 4-hydroxymethyl-2-pyrrolidone was used instead of 4-hydroxy-2-pyrrolidone to obtain compound 2.

[0282] 1H NMR(500MHz,DMSO-d6)δ8.10-8.08(m,2H),7.91(d,J=9.0Hz,1H),7.82(d,J= 8.3Hz,1H),7.73(d,J=8.4Hz,2H),7.53(t,J=7.9Hz,1H),7.15-7.13(m,3H), 4.90(t,J=5.2Hz,1H),4.05-4.01(m,1H),3.78-3.75(m,1H),3.53-3.45(m,2 H),2.69-2.63(m,1H),2.62-2.55(m,1H),2.39-2.35(m,1H).MS(ESI+,[M+H] + )m / z:402.12.

[0283] Compound 2 was separated by high pressure preparative liquid chromatography (REFLECT I-Amylose A column; ethanol:n-hexane=30:70). The first eluting peak was compound 2_A (40 mg) and the second eluting peak was compound 2_B (42 mg).

[0284] Compound 2_A: 1 H NMR(500MHz,DMSO-d6)δ8.10-8.08(m,2H),7.91(d,J=9.0Hz,1H),7.82(d,J= 8.3Hz,1H),7.73(d,J=8.8Hz,2H),7.53(t,J=7.9Hz,1H),7.15-7.13(m,3H), 4.90(t,J=5.2Hz,1H),4.05-4.01(m,1H),3.78-3.75(m,1H),3.53-3.44(m,2 H),2.69-2.64(m,1H),2.61-2.56(m,1H),2.39-2.35(m,1H).MS(ESI+,[M+H] + )m / z:402.16.

[0285] Compound 2_B: 1H NMR(500MHz,DMSO-d6)δ8.10-8.08(m,2H),7.91(d,J=9.0Hz,1H),7.82(d,J= 8.3Hz,1H),7.73(d,J=8.7Hz,2H),7.53(t,J=7.9Hz,1H),7.15-7.13(m,3H), 4.90(t,J=5.2Hz,1H),4.05-4.01(m,1H),3.78-3.75(m,1H),3.53-3.46(m,2 H),2.69-2.63(m,1H),2.61-2.56(m,1H),2.39-2.35(m,1H).MS(ESI+,[M+H] + )m / z:402.16.

[0286] Example 3

[0287] Referring to the synthesis of Example 1, in step B, 4-hydroxy-2-pyrrolidone was replaced with isothiazolidine 1,1-dioxide. The resulting crude product was purified by silica gel column chromatography to obtain compound 3 (238 mg).

[0288] 1 H NMR (500MHz, DMSO-d6) δ7.95(d,J=9.1Hz,1H),7.80(d,J=8.3Hz,1H),7.73(d,J=8.6Hz,2H),7.66(d,J=2.3Hz,1H),7.61-7. 50(m,2H),7.13(dd,J=12.5,8.0Hz,3H),3.89(t,J=6.5Hz,2H),3.58(t,J=7.4Hz,2H),2.46(q,J=7.0Hz,2H).MS(ESI+,[M+H] + )m / z:408.09.

[0289] Example 4 (4_A and 4_B)

[0290] Referring to the synthesis of Example 1, in step B, 4-hydroxy-2-pyrrolidone was replaced with 3-(hydroxymethyl)pyrrolidin-2-one. The resulting crude product was subjected to high-pressure preparative liquid separation (REFLECT I-Amylose A column; ethanol:n-hexane = 22:78). The first eluting peak was compound 4_A (80 mg), and the later eluting peak was compound 4_B (80 mg).

[0291] Compound 4_A: 1H NMR (500MHz, DMSO-d6) δ8.13(d,J=2.1Hz,1H),7.92(d,J=9.1Hz,1H),7.84-7.77(m,2H),7. 76-7.69(m,2H),7.61-7.52(m,1H),7.19-7.12(m,3H),4.86(t,J=5.3Hz,1H),4.49(ddt,J=7 .9,4.4,3.0Hz,1H),3.58-3.41(m,2H),2.64(ddd,J=16.9,9.9,8.4Hz,1H),2.40(ddd,J=16. 9,10.1,4.3Hz,1H),2.24(ddt,J=12.6,10.1,8.5Hz,1H),2.18-2.02(m,1H).MS(ESI+,[M+H] + )m / z:402.24.

[0292] Compound 4_B: 1 H NMR(500MHz,DMSO-d6)δ8.13(d,J=2.1Hz,1H),7.92(d,J=9.1Hz,1H),7.84-7.76(m,2H),7.73 (d,J=8.8Hz,2H),7.54(t,J=7.9Hz,1H),7.23-7.11(m,3H),4.86(t,J=5.3Hz,1H),4.58-4.43( m,1H),3.58-3.42(m,2H),2.64(ddd,J=16.9,9.9,8.5Hz,1H),2.40(ddd,J=16.9,10.1,4.3Hz ,1H),2.24(ddt,J=12.6,10.0,8.5Hz,1H),2.07(ddt,J=13.1,9.9,3.7Hz,1H).MS(ESI+,[M+H] + )m / z:402.15.

[0293] Example 5

[0294] Referring to the synthesis of Example 1, in step B, 1-methylimidazolidin-2-one was used instead of 4-hydroxy-2-pyrrolidone, and the obtained crude product was separated by medium-low pressure preparative liquid phase to obtain compound 5 (215 mg).

[0295] Compound 5: 1H NMR(500MHz,DMSO-d6)δ8.18-8.16(m,1H),7.87-7.83(m,2H),7.75-7.71(m,3H),7.51-7.47(m,1H),7.13( d,J=8.7Hz,2H),7.06(d,J=7.3Hz,1H),3.93-3.90(m,2H),3.52-3.49(m,2H),2.80(s,3H).MS(ESI+,[M+H] + )m / z:387.16.

[0296] Example 6 (6_A and 6_B)

[0297] Referring to the synthesis of Example 1, in step B, 4-hydroxy-2-pyrrolidone was replaced with 3-(hydroxymethyl)pyrrolidin-2-one. The resulting crude product was subjected to high-pressure preparative liquid separation (REFLECT I-Amylose A column; ethanol:n-hexane = 22:78). The first eluting peak was compound 6_A (40 mg), and the later eluting peak was compound 6_B (42 mg).

[0298] Compound 6_A: 1 H NMR(500MHz,DMSO-d6)δ8.12(d,J=2.0Hz,1H),8.09(dd,J=9.2,2.2Hz,1H),7.92(d,J=9.2 Hz,1H),7.81(d,J=8.3Hz,1H),7.73(d,J=8.7Hz,2H),7.53(t,J=7.9Hz,1H),7.20-7.11(m ,3H),4.83(t,J=5.2Hz,1H),3.97-3.88(m,2H),3.76(dt,J=10.7,6.7Hz,1H),3.69-3.62( m,1H),2.81-2.71(m,1H),2.29-2.20(m,1H),2.12(dq,J=12.5,8.2Hz,1H).MS(ESI+,[M+H] + )m / z:402.07.

[0299] Compound 6_B: 1H NMR (500MHz, DMSO-d6) δ8.12(d,J=2.0Hz,1H),8.09(dd,J=9.2,2.1Hz,1H),7.92(d,J=9.2 Hz,1H),7.81(d,J=8.3Hz,1H),7.73(d,J=8.7Hz,2H),7.53(t,J=7.9Hz,1H),7.18-7.11(m ,3H),4.83(t,J=5.2Hz,1H),3.96-3.88(m,2H),3.75(dt,J=10.7,5.4Hz,1H),3.70-3.62( m,1H),2.83-2.68(m,1H),2.31-2.20(m,1H),2.12(dq,J=12.4,8.2Hz,1H).MS(ESI+,[M+H] + )m / z:402.16.

[0300] Example 7 (7_A and 7_B)

[0301] Referring to the synthesis of Example 1, in step B, 4-hydroxy-2-pyrrolidone was replaced with 5-hydroxy-2-piperidone. The resulting crude product was subjected to high-pressure preparative liquid separation (REFLECT I-Amylose A column; ethanol:n-hexane = 22:78). The first eluting peak was compound 7_A (30 mg), and the later eluting peak was compound 7_B (30 mg).

[0302] Compound 7_A: 1 H NMR (500MHz, DMSO-d6) δ7.70(d,J=8.7Hz,2H),7.61(d,J=9.1Hz,1H),7.50(d,J=8.3Hz,1H),7. 37-7.31(m,1H),7.09(d,J=8.6Hz,2H),7.05(dd,J=9.1,2.3Hz,1H),6.91(d,J=2.2Hz,1H),6.82 (dd,J=7.5,0.7Hz,1H),6.37(t,J=5.9Hz,1H),4.75(qd,J=7.0,4.4Hz,1H),3.48-3.34(m,2H), 2.58-2.51(m,2H),2.31(dddd,J=12.6,9.1,7.0,5.5Hz,1H),2.04-1.94(m,1H).MS(ESI+,[M+H] + )m / z:402.13.

[0303] Compound 7_B: 1H NMR(500MHz,DMSO-d6)δ7.70(d,J=8.7Hz,2H),7.60(d,J=9.1Hz,1H),7.50(d,J=8.3Hz,1H), 7.38-7.31(m,1H),7.08(d,J=8.6Hz,2H),7.04(dd,J=9.1,2.2Hz,1H),6.91(d,J=2.1Hz,1H), 6.84-6.79(m,1H),6.36(t,J=5.9Hz,1H),4.79-4.71(m,1H),3.48-3.34(m,2H),2.54(dd,J=1 1.1,6.6Hz,2H),2.31(dddd,J=12.5,9.1,7.0,5.5Hz,1H),2.04-1.93(m,1H).MS(ESI+,[M+H] + )m / z:402.13.

[0304] Example 8

[0305] Referring to the synthesis of Example 1, in step B, 4-methylpiperazine-2-one was used instead of 4-hydroxy-2-pyrrolidone. The obtained crude product was separated by medium-low pressure preparative separation to obtain compound 8 (246 mg).

[0306] 1 H NMR (500MHz, DMSO-d6) δ8.19(d,J=2.0Hz,1H),8.10(d,J=9.0Hz,1H),8.03(d,J=8.3Hz,1H),7.92(d,J=8.7Hz,2H),7.79-7.71( m,2H),7.45-7.42(m,1H),7.33(d,J=8.6Hz,2H),4.00-3.94(m,2H),3.51(s,2H),3.00-2.93(m,2H),2.73-2.65(m,3H).MS(ESI + ,[M+H] + )m / z:401.15.

[0307] Example 9 (9_A and 9_B)

[0308] Referring to the synthesis of Example 1, in step B, 4-hydroxy-2-piperidone was used instead of 4-hydroxy-2-pyrrolidone. The resulting crude product was subjected to high-pressure preparative liquid separation (REFLECT I-Amylose A column; ethanol:n-hexane = 22:78). The first eluting peak was compound 9_A (36 mg), and the later eluting peak was compound 9_B (33 mg).

[0309] Compound 9_A: 1 H NMR (500MHz, DMSO-d6) δ7.93-7.88(m,2H),7.84(d,J=8.3Hz,1H),7.73(d,J=8.6Hz,2H ),7.58-7.54(m,1H),7.49-7.47(m,1H),7.22(d,J=7.5Hz,1H),7.15(d,J=8.5Hz,2H), 5.13(d,J=3.6Hz,1H),4.17-4.12(m,1H),3.90-3.85(m,1H),3.67-3.62(m,1H),2.71- 2.66(m,1H),2.38-2.33(m,1H),2.09-2.07(m,1H),1.91-1.84(m,1H).MS(ESI+,[M+H] + )m / z:402.16.

[0310] Compound 9_B: 1 H NMR (500MHz, DMSO-d6) δ7.93-7.88(m,2H),7.84(d,J=8.3Hz,1H),7.73(d,J=8.7Hz,2H ),7.58-7.54(m,1H),7.49-7.47(m,1H),7.22(d,J=7.5Hz,1H),7.15(d,J=8.6Hz,2H), 5.13(d,J=3.6Hz,1H),4.17-4.12(m,1H),3.90-3.85(m,1H),3.67-3.62(m,1H),2.71- 2.66(m,1H),2.38-2.33(m,1H),2.09-2.07(m,1H),1.91-1.85(m,1H).MS(ESI+,[M+H] + )m / z:402.15.

[0311] Example 10 (10_A and 10_B)

[0312] Referring to the synthesis of Example 1, in step B, 4-hydroxy-2-pyrrolidone was replaced with 3-hydroxymethylpyridine. The resulting crude product was subjected to high-pressure preparative liquid separation (CHIRALPAK IG column; ethanol:n-hexane = 20:80). The first eluting peak was compound 10_A (15 mg), and the last eluting peak was compound 10_B (15 mg).

[0313] Compound 10_A: 11H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 9.1 Hz, 1H), 7.53 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 8.3 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.03 (d, J = 8.6 Hz, 2H), 6.96 (dd, J = 9.2, 2.3 Hz, 1H), 6.80 (d, J = 2.1 Hz, 1H), 6.76 (d, J = 7.3 Hz, 1H), 3.72 (ddd, J = 26.6, 10.4, 6.9 Hz, 2H), 3.57 (dd, J = 9.2, 7.7 Hz, 1H), 3.51 (td, J = 8.6, 4.8 Hz, 1H), 3.43 (dd, J = 16.5, 7.5 Hz, 1H), 3.26 (dd, J = 9.4, 6.4 Hz, 1H), 2.63 (dt, J = 13.8, 6.9 Hz, 1H), 2.20 (dtd, J = 12.2, 7.4, 5.0 Hz, 1H), 1.93 - 1.85 (m, 1H). MS (ESI+, [M+H] + ) m / z: 388.14.

[0314] Compound 10_B: 1 1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 9.1 Hz, 1H), 7.53 (d, J = 8.7 Hz, 2H), 7.49 (d, J = 8.3 Hz, 1H), 7.35 (d, J = 2.4 Hz, 1H), 7.03 (d, J = 8.6 Hz, 2H), 6.96 (dd, J = 9.2, 2.4 Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 6.76 (d, J = 7.2 Hz, 1H), 3.73 (ddd, J = 26.6, 10.4, 6.9 Hz, 2H), 3.57 (dd, J = 9.4, 7.6 Hz, 1H), 3.51 (td, J = 8.7, 4.8 Hz, 1H), 3.43 (dd, J = 12.0, 4.5 Hz, 1H), 3.26 (dd, J = 9.4, 6.3 Hz, 1H), 2.62 (dd, J = 13.9, 7.0 Hz, 1H), 2.28 - 2.16 (m, 1H), 1.88 (dd, J = 12.4, 7.6 Hz, 1H). MS (ESI+, [M+H] + ) m / z: 388.11.

[0315] Example 11 (11_A and 11_B)

[0316] Referring to the synthesis of Example 1, in step B, 4-hydroxy-2-piperidone was used instead of 4-hydroxy-2-pyrrolidone, and the resulting crude product was subjected to high-pressure preparative liquid separation ((R,R)-Whelk-O1 column; ethanol:n-hexane = 50:50). The first eluting peak was compound 11_A (154 mg), and the later eluting peak was compound 11_B (168 mg).

[0317] Compound 11_A: 1 H NMR (500MHz, DMSO-d6) δ8.15 (d, J=2.0Hz, 1H), 8.12-8.10 (m, 1H), 7.94 (d, J= 9.2Hz,1H),7.83(d,J=8.3Hz,1H),7.73(d,J=8.7Hz,2H),7.56-7.53(m,1H), 7.16-7.13(m,3H),5.81(d,J=5.9Hz,1H),4.39-4.34(m,1H),3.91-3.87(m,1 H),3.85-3.80(m,1H),2.49-2.43(m,1H),1.95-1.87(m,1H).MS(ESI+,[M+H] + )m / z:388.13.

[0318] Compound 11_B: 1 H NMR (500MHz, DMSO-d6) δ8.15 (d, J=2.0Hz, 1H), 8.12-8.10 (m, 1H), 7.94 (d, J= 9.2Hz,1H),7.83(d,J=8.3Hz,1H),7.73(d,J=8.8Hz,2H),7.56-7.53(m,1H), 7.16-7.13(m,3H),5.81(d,J=5.9Hz,1H),4.39-4.34(m,1H),3.91-3.87(m,1 H),3.85-3.80(m,1H),2.48-2.43(m,1H),1.95-1.87(m,1H).MS(ESI+,[M+H] + )m / z:388.13.

[0319] Example 12

[0320] Referring to the synthesis of Example 1, in step B, pyrrolidone was used instead of 4-hydroxy-2-pyrrolidone. The obtained crude product was purified by silica gel column chromatography to obtain compound 12 (34.5 mg).

[0321] 1H NMR (500MHz, DMSO-d6) δ8.11(d,J=1.6Hz,1H),8.08-8.06(m,1H),7.92(d,J=9.2Hz,1H),7.81(d,J=8.3Hz,1H),7.73(d,J= 8.6Hz,2H),7.55-7.52(m,1H),7.15-7.13(m,3H),3.98-3.95(m,2H),2.58-2.54(m,2H),2.15-2.09(m,2H).MS(ESI+,[M+H] + )m / z:372.13.

[0322] Example 13

[0323] Step A: Referring to the synthesis of Example 1, in step B, tert-butyl 3-oxo-2,8-diazaspiro[4,5]decane-8-carboxylate was used instead of 4-hydroxy-2-pyrrolidone. The resulting crude product was purified by silica gel column chromatography (EA / PE) to obtain intermediate 13-1 (250 mg). MS (ESI+, [M+H] + )m / z:541.01.

[0324] Step B: To a single-necked flask, 13-1 (250 mg) and a 4 M hydrogen chloride-dioxane solution (5 mL) were added sequentially and the mixture was stirred at room temperature for 0.5 h. After completion of the reaction, the reaction solution was concentrated, diluted with water (50 mL), and the pH was adjusted to 8-9 with 1 M sodium hydroxide solution. The mixture was extracted with EA, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography to obtain compound 13 (125 mg).

[0325] 1 H NMR (500MHz, DMSO-d6) δ8.10-8.07(m,2H),7.90(d,J=9.0Hz,1H),7.81(d,J=8.2Hz,1H),7.73(d,J=8.7Hz,2H),7.5 5-7.52(m,1H),7.15-7.12(m,3H),3.78(s,2H),2.74-2.68(m,4H),2.49(s,2H),1.63-1.55(m,4H).MS(ESI+,[M+H] + )m / z:441.17.

[0326] Example 14

[0327] Step A: Referring to the synthesis of Example 1, in step B, 14-1 was used instead of 4-hydroxy-2-pyrrolidone, and the obtained crude product was purified by silica gel column chromatography (PE / EA) to obtain compound 14-2 (210 mg).

[0328] Step B: 14-2 (210 mg) and hydrogen chloride (6.9 mL, 4 M 1,4-dioxane solution) were added sequentially to an eggplant-shaped flask and reacted at room temperature for 2 hours under N2 protection. After the reaction, 20 mL of saturated sodium bicarbonate aqueous solution was added, and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain compound 14 (141 mg).

[0329] 1 H NMR(500MHz,DMSO-d6)δ8.09(d,J=2.1Hz,1H),8.08-8.04(m,1H),7.91(d,J= 9.1Hz,1H),7.81(d,J=8.3Hz,1H),7.75-7.70(m,2H),7.53(t,J=7.9Hz,1H), 7.17-7.12(m,3H),4.09-4.04(m,1H),3.72-3.68(m,1H),3.58-3.54(m,1H), 2.79-2.75(m,1H),2.28-2.24(m,1H),1.97(d,J=14.8Hz,2H).MS(ESI+,[M+H] + )m / z:387.13.

[0330] Example 15

[0331] Step A: Referring to the synthesis of Example 1, in step B, 15-1 was used instead of 4-hydroxy-2-pyrrolidone, and the obtained crude product was purified by silica gel column chromatography (MeOH / DCM) to obtain compound 15-2 (305 mg).

[0332] Step B: Referring to step B of Example 14, intermediate 15-2 was substituted for intermediate 14-2 to obtain compound 15 (220 mg).

[0333] 1H NMR (500MHz, DMSO-d6) δ7.97(d,J=2.1Hz,1H),7.91(d,J=9.0Hz,1H),7.84(d,J=8.3Hz,1H),7.73(d,J=8.7Hz,2H),7.59-7.53(m, 2H),7.25-7.21(m,1H),7.14(d,J=8.6Hz,2H),3.72(t,J=5.4Hz,2H),3.44(s,2H),3.09-3.01(m,2H),2.83(s,1H).MS(ESI+,[M+H] + )m / z:387.13.

[0334] Example 16

[0335] Step A: Referring to the operation of step B of Example 1, 4-hydroxy-2-pyrrolidone was replaced with 3-hydroxy-2-pyrrolidone, and the reaction was carried out at 100°C overnight. After the reaction was completed, the filter cake was washed with ethyl acetate, the filtrate was collected, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The compound 11 (224 mg) was purified by silica gel column chromatography.

[0336] 1 H NMR(500MHz,DMSO-d6)δ8.15(d,J=2.2Hz,1H),8.11(dd,J=9.2,2.2Hz,1H),7.94(d, J=9.2Hz,1H),7.83(d,J=8.3Hz,1H),7.73(d,J=8.9Hz,2H),7.54(t,J=7.9Hz,1H),7 .17-7.13(m,3H),5.81(d,J=5.9Hz,1H),4.36(ddd,J=9.1,8.0,5.9Hz,1H),3.90-3. 86(m,1H),3.85-3.81(m,1H),2.49-2.41(m,1H),1.93-1.88(m,1H).MS(ESI+,[M+H] + )m / z:388.12.

[0337] Step B: 11 (140 mg), dichloromethane (5 mL), pyridine (0.012 mL) and dichlorothionyl (172 mg) were added to the reaction flask in sequence and reacted at room temperature overnight. After the reaction, saturated aqueous sodium bicarbonate solution (20 mL) was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EA) to obtain 16-1 (127 mg). 1H NMR (500MHz, DMSO-d6) δ8.20(d,J=2.2Hz,1H),8.04(dd,J=9.2,2.2Hz,1H),7.97(d,J=9.1Hz,1H),7.85(d,J=8.3Hz,1H),7.74(d,J=8.7Hz,2H),7.57 (t,J=7.9Hz,1H),7.19(d,J=7.1Hz,1H),7.15(d,J=8.6Hz,2H),4.94(dd,J =7.7,6.0Hz,1H),4.20-3.92(m,2H),2.82-2.78(m,1H),2.34-2.29(m,1H).

[0338] Step C: 16-1 (127 mg), K2CO3 (130 mg), KI (120 mgl), acetonitrile (5 mL) and 1,2-ethylenediamine (200 mg) were added to the reaction flask in sequence. Under N2 protection, the mixture was heated to 80°C for 6 h. After the reaction, 30 mL of water was added to quench the reaction, and then ethyl acetate was added for extraction. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain compound 16 (120 mg).

[0339] 1 H NMR(500MHz,DMSO-d6)δ8.14(d,J=2.2Hz,1H),8.09(dd,J=9.2,2.2Hz,1H),7.94(d ,J=9.2Hz,1H),7.82(d,J=8.3Hz,1H),7.73(d,J=8.5Hz,2H),7.55(t,J=7.9Hz,1H), 7.17-7.13(m,3H),5.58(s,3H),3.96-3.84(m,2H),3.61(t,J=8.8Hz,1H),2.96-2. 88(m,1H),2.89-2.75(m,3H),2.49-2.39(m,1H),1.93-1.80(m,1H).MS(ESI+,[M+H] + )m / z:430.17.

[0340] Example 17

[0341] Step A: 11 (80 mg) and THF (2 mL) were added to the reaction flask in sequence. The reaction solution was placed in an ice bath and cooled, and then NaH (12 mg) was added. After stirring for 10 min, a solution of MeI (0.026 mL) in THF (2 mL) was slowly added dropwise. Under N2 protection, the temperature was raised to room temperature and the reaction was allowed to react for 1.5 h. After the reaction was completed, 10 mL of saturated aqueous ammonium chloride was added to quench the reaction, and then extracted with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The resulting crude product was purified by silica gel column chromatography to obtain compound 17 (10 mg).

[0342] 1 H NMR(500MHz,DMSO-d6)δ8.17(d,J=2.2Hz,1H),8.06(dd,J=9.2,2.2Hz,1H),7. 94(d,J=9.2Hz,1H),7.83(d,J=8.3Hz,1H),7.73(d,J=8.4Hz,2H),7.55(t,J=7. 9Hz,1H),7.17-7.13(m,3H),4.20(t,J=8.0Hz,1H),3.95-3.89(m,1H),3.89-3 .82(m,1H),3.49(s,3H),2.56-2.51(m,1H),2.04-1.93(m,1H).MS(ESI+,[M+H] + )m / z:402.08.

[0343] Example 18

[0344] Step A: Referring to the synthesis of Example 1, in step B, tert-butyloxycarbonyl-3-amino-2-pyrrolidone was used instead of 4-hydroxy-2-pyrrolidone. The obtained crude product was purified by silica gel column chromatography (PE / EA) to obtain compound 18-1 (210 mg).

[0345] Step B: To an eggplant-shaped flask were added 18-1 (210 mg) and 4 M hydrochloric acid dioxane solution (4 mL) in sequence. The mixture was stirred at room temperature for 1 h, and water (30 mL) was added to the reaction solution. The pH was adjusted to 8-9 with saturated Na2CO3 aqueous solution, and then extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give compound 18 (150 mg).

[0346] 1H NMR (500MHz, DMSO-d6) δ8.19-8.09(m,2H),7.93(d,J=9.1Hz,1H),7.82(d,J=8.3Hz,1H),7.73(d,J=8.6Hz,2H),7.54(t,J=7.9Hz, 1H),7.20-7.09(m,3H),3.92-3.79(m,2H),3.64-3.56(m,1H),2.47-2.37(m,1H),2.03(s,2H),1.88-1.73(m,1H).MS(ESI+,[M+H] + )m / z:387.17.

[0347] Example 19

[0348] Step A: Referring to the synthesis of Example 1, in step B, 2-oxa-6-azaspiro[3.4]octan-7-one was used instead of 4-hydroxy-2-pyrrolidone to obtain compound 19 (120 mg).

[0349] 1 H NMR (500MHz, DMSO-d6) δ8.11(d,J=2.2Hz,1H),8.06(dd,J=9.2,2.2Hz,1H),7.92(d,J=9.2Hz,1H),7.82(d,J=8.3Hz,1H),7.73(d,J =8.5Hz,2H),7.57-7.51(m,1H),7.19-7.09(m,3H),4.71-4.63(m,2H),4.28(s,2H),2.98(s,2H),2.55-2.46(m,2H).MS(ESI-,[M+H] - )m / z:412.31.

[0350] Example 20

[0351] Step A: 18-1 (100 mg), dichloromethane (5 mL), iodomethane (30 mg), NaH (20 mg), and DMF (1 mL) were added to an eggplant-shaped flask in sequence. After stirring at room temperature for 6 h, water (30 mL) was added to the reaction solution and extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 20-1 (100 mg). MS (ESI+, [M+H] + )m / z:501.46.

[0352] Step B: Referring to step B of Example 18, intermediate 20-1 was substituted for 18-1 to obtain compound 20 (150 mg).

[0353] 1 H NMR (500MHz, DMSO-d6) δ8.14(d,J=2.2Hz,1H),8.09(dd,J=9.2,2.2Hz,1H),7.93(d,J=9.2Hz,1H),7.82(d,J=8.3Hz,1H),7.73(d,J=8.6H z,2H),7.59-7.48(m,1H),7.21-7.08(m,3H),3.98-3.79(m,2H),3.54-3.45(m,1H),2.44-2.32(m,4H),1.96-1.75(m,1H).MS(ESI+,[M+H] + )m / z:401.48.

[0354] Example 21 (21_A and 21_B)

[0355] Step A: Referring to the synthesis of Example 1, in step B, 4-hydroxy-2-pyrrolidone was replaced with 4-oxoazetidine-2-carboxylic acid benzyl ester. The resulting crude product was purified by silica gel column chromatography (EA / PE) to obtain intermediate 21-1 (184 mg). MS (ESI+, [M+H] + )m / z:492.13.

[0356] Step B: To a single-necked flask, 21-1 (184 mg) and MeOH (5 mL) were added sequentially. Under N2 protection, the temperature was lowered to 0°C, and then sodium borohydride (28 mg) was added in batches. After the addition was complete, stirring was continued for 1 h. After the reaction was completed, the reaction solution was slowly poured into an ice-cold saturated ammonium chloride solution (20 mL), extracted with EA, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography to obtain compound 21 (100 mg).

[0357] Step C: Compound 21 was separated by high pressure preparative liquid chromatography (REFLECT I-Amylose A column; ethanol:n-hexane = 30:70). The first eluting peak was compound 21_A (49 mg) and the second eluting peak was compound 21_B (49 mg).

[0358] Compound 21_A: 1H NMR (500MHz, DMSO-d6) δ7.94-7.92(m,2H),7.83-7.77(m,2H),7.73(d,J=8.7Hz,2H),7.52(t,J=7.8Hz,1H),7.14-7.10(m,3H),5.0 6(t,J=5.4Hz,1H),4.37-4.34(m,1H),3.98-3.94(m,1H),3.76-3.72(m,1H),3.18-3.14(m,1H),2.97-2.94(m,1H).MS(ESI+,[M+H] + )m / z:387.96.

[0359] Compound 21_B: 1 H NMR (500MHz, DMSO-d6) δ7.94-7.92(m,2H),7.83-7.77(m,2H),7.73(d,J=8.7Hz,2H),7.52(t,J=7.9Hz,1H),7.14-7.10(m,3H),5.0 6(t,J=5.4Hz,1H),4.37-4.34(m,1H),3.98-3.94(m,1H),3.76-3.72(m,1H),3.18-3.14(m,1H),2.97-2.93(m,1H).MS(ESI+,[M+H] + )m / z:387.96.

[0360] Example 22 (22_A and 22_B)

[0361] Step A: To a single-necked flask, 22-1 (5.0 g), 1-(4-methoxyphenyl)ethylamine (5.87 g), and NMP (30 mL) were added sequentially. Under N2 protection, the mixture was heated to 80°C for 1 h, then heated to 120°C and stirred for 4 h. After the reaction, the reaction solution was cooled to room temperature and then slowly poured into 300 mL of water. The filter cake was filtered and washed with petroleum ether. The intermediate 22-2 (7.85 g) was obtained by drying under reduced pressure. MS (ESI-, [MH]) - )m / z:262.19.

[0362] Step B: To a single-necked flask, 22-2 (7.7 g), DMF (40 mL), benzyl bromide (5.5 g) and cesium carbonate (10.5 g) were added in sequence. After the addition, the mixture was stirred at room temperature for 1 h. After the reaction, the reaction solution was poured into 200 mL of water and extracted with EA. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude product was purified by silica gel column chromatography (EA / PE) to obtain intermediate 22-3 (10.3 g). MS (ESI+, [M+H] + )m / z:354.41.

[0363] Step C: To a single-necked flask, 22-3 (1.0 g) and DMF (10 mL) were added sequentially. Under N2 protection, the temperature was lowered to 0°C, and then sodium hydride (60% wt purity, 0.45 g) was added in batches. After 10 minutes, iodomethane (4.02 g) was added dropwise. After the addition was complete, the mixture was heated to 40°C and reacted for 18 hours. After the reaction, the reaction solution was cooled to room temperature and then slowly poured into 100 mL of ice-cold saturated ammonium chloride solution. The mixture was extracted with EA, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude product was purified by silica gel column chromatography (EA / PE) to obtain intermediate 22-4 (800 mg). MS (ESI+, [M+H] + )m / z:368.44.

[0364] Step D: To a single-necked flask, 22-4 (800 mg) and MeOH (20 mL) were added sequentially. Under N2 protection, the temperature was lowered to 0°C, and then sodium borohydride (285 mg) was added in batches. After the addition, stirring was continued for 2 h. After the reaction was completed, the reaction solution was slowly poured into an ice-cold saturated ammonium chloride solution (100 mL), extracted with EA, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The resulting crude product was purified by silica gel column chromatography (MeOH / DCM) to obtain intermediate 22-5 (570 mg). MS (ESI+, [M+H] + )m / z:264.40.

[0365] Step E: To a single-necked flask, 22-5 (570 mg) and trifluoroacetic acid (13 g) were added in sequence, and the reaction solution was heated to 80°C and stirred for 24 h. After the reaction, the reaction solution was directly concentrated to dryness under reduced pressure to obtain intermediate 22-6 (279 mg). MS (ESI+, [M+Na] + )m / z:151.95.

[0366] Step F: Referring to the synthesis of Example 1, in step B, 22-6 was used instead of 4-hydroxy-2-pyrrolidone. The resulting crude product was purified by silica gel column chromatography to give compound 22 (375 mg). MS (ESI+, [M+H]+ )m / z:416.26.

[0367] Step G: Compound 22 was further subjected to high pressure preparative liquid separation (REFLECT I-Amylose A column; ethanol:n-hexane = 30:70). The first eluting peak was compound 22_A (189 mg) and the second eluting peak was compound 22_B (175 mg).

[0368] Compound 22_A: 1 H NMR(500MHz,DMSO-d6)δ8.09-8.07(m,2H),7.92-7.90(m,1H),7.81(d,J=8.4H z,1H),7.73(d,J=8.7Hz,2H),7.53(t,J=7.8Hz,1H),7.15-7.12(m,3H),5.03(t ,J=5.4Hz,1H),3.88(d,J=9.7Hz,1H),3.61(d,J=9.7Hz,1H),3.36-3.34(m,2H ),2.55(d,J=16.9Hz,1H),2.32(d,J=16.9Hz,1H),1.16(s,3H).MS(ESI+,[M+H] + )m / z:416.26.

[0369] Compound 22_B: 1 H NMR(500MHz,DMSO-d6)δ8.09-8.07(m,2H),7.92-7.90(m,1H),7.81(d,J=8.3H z,1H),7.73(d,J=8.8Hz,2H),7.53(t,J=7.9Hz,1H),7.15-7.12(m,3H),5.03(t ,J=5.4Hz,1H),3.88(d,J=9.7Hz,1H),3.61(d,J=9.7Hz,1H),3.36-3.34(m,2H ),2.55(d,J=16.9Hz,1H),2.32(d,J=16.9Hz,1H),1.16(s,3H).MS(ESI+,[M+H] + )m / z:416.25.

[0370] Example 23 (23_A and 23_B)

[0371] Step A: Under a nitrogen atmosphere, lithium diisopropylamide (23.3 mL, 2 M tetrahydrofuran solution) was added to a three-necked flask. A tetrahydrofuran solution (50 mL) of 23-1 (4.9 g) was added at -78°C, and the mixture was stirred for 0.5 hours. N-phenylbis(trifluoromethanesulfonimide) (14.8 g) was added, and the mixture was stirred for 0.5 hours, then transferred to 0°C and stirred for 1 hour. After the reaction was completed, 50 mL of saturated aqueous ammonium chloride was added, and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 23-2 (9.45 g).

[0372] Step B: To an eggplant-shaped flask, 23-2 (9.45 g), N,N-dimethylformamide (40 mL), methanol (80 mL), triethylamine (14.4 mL), and bis(triphenylphosphine)palladium(II) dichloride (1.07 g) were added in sequence. The air in the reaction vessel was replaced with carbon monoxide at atmospheric pressure, and the reaction solution was stirred at 50°C for 18 hours. After the reaction, 50 mL of purified water was added, and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 23-3 (6.35 g).

[0373] Step C: To an eggplant-shaped flask, 23-3 (6.35 g), toluene (100 mL), and 2,4-dimethoxybenzylamine (5.18 mL) were added sequentially, and the reaction solution was stirred at 110°C for 18 hours. After the reaction was completed, the crude product was cooled to room temperature and purified by silica gel column chromatography (PE / EA) to obtain compound 23-4 (330 mg).

[0374] Step D: Compound 23-4 (300 mg) and trifluoroacetic acid (7.2 mL) were added to an eggplant-shaped flask in sequence, and the reaction solution was stirred at 80° C. for 3 hours. After the reaction was completed and cooled to room temperature, the reaction solution was concentrated under reduced pressure to dryness to obtain compound 23-5 (159 mg).

[0375] Step E: Referring to the synthesis of Example 1, in step B, 23-5 was used instead of 4-hydroxy-2-pyrrolidone, and the obtained crude product was purified by silica gel column chromatography to obtain compound 23-6 (300 mg).

[0376] Step F: 23-6 (300 mg), methanol (2 mL), and sodium borohydride (125 mg) were added to an eggplant-shaped flask in sequence. The reaction solution was stirred at room temperature for 18 hours. After the reaction was completed, 30 mL of purified water was added, and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 23 (170 mg). MS (ESI+, [M+H] + )m / z:428.22.

[0377] Step G: Compound 23 (170 mg) was separated by high pressure preparative liquid chromatography (REFLECT I-Amylose A column; ethanol:n-hexane = 7:93). The first eluting peak was compound 23_A (76 mg), and the second eluting peak was compound 23_B (76 mg).

[0378] Example 23_A: 1 H NMR (500MHz, DMSO) δ8.16-8.09(m,2H),7.91(d,J=9.1Hz,1H),7.81(d,J=8.3Hz,1H ),7.73(d,J=8.7Hz,2H),7.55-7.50(m,1H),7.17-7.11(m,3H),4.82-4.78(m,1H),4 .16-4.12(m,1H),3.89-3.84(m,1H),3.50-3.45(m,1H),3.43-3.38(m,1H),1.24-1. 21(m,1H),1.17-1.11(m,1H),1.02-0.97(m,1H),0.91-0.85(m,2H).MS(ESI+,[M+H] + )m / z:428.15.

[0379] Example 23_B: 1 H NMR (500MHz, DMSO) δ8.16-8.09(m,2H),7.91(d,J=9.1Hz,1H),7.81(d,J=8.3H z,1H),7.76-7.69(m,2H),7.57-7.49(m,1H),7.16-7.12(m,3H),4.82-4.78(m ,1H),4.16-4.12(m,1H),3.89-3.84(m,1H),3.52-3.37(m,2H),1.24-1.21(m, 1H),1.18-1.13(m,1H),1.02-0.97(m,1H),0.91-0.85(m,2H).MS(ESI+,[M+H] + )m / z:428.15.

[0380] Example 24 (24_A and 24_B)

[0381] Step A: Under nitrogen, 24-1 (4.0 g), 24-2 (2.00 g), and alumina-supported potassium fluoride (1.0 g) were added sequentially to a microwave tube. The reaction was allowed to proceed at room temperature for 24 h. The system was directly filtered, and the filtrate was collected and concentrated to afford 24-3 (2.8 g). 1H NMR(500MHz,DMSO-d6)δ4.13-4.07(m,2H),4.07-4.00(m,2H),3.53-3.47(m,1H),2.73-2.65(m, 1H),2.66-2.58(m,1H),1.58(s,3H),1.53(s,3H),1.17(t,J=7.1Hz,3H),1.14(t,J=7.1Hz,3H).

[0382] Step B: To a single-necked flask, under nitrogen atmosphere and in an ice bath, 24-3 (2.8 g), anhydrous methanol (50 mL), and nickel chloride hexahydrate (2.55 g) were added sequentially. Sodium borohydride (3.24 g) was added portionwise. After addition, the mixture was stirred at room temperature for 1 h. The reaction was quenched by adding 50 mL of saturated ammonium chloride solution, concentrated to remove methanol, and then extracted with EA. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to afford 24-4 (1.5 g). 1 HNMR(500MHz,DMSO-d6)δ7.79(s,1H),4.19-4.12(m,1H),4.12-4.05(m,1H),3.04(t,J=9.0Hz,1H), 2.59-2.51(m,1H),2.31-2.25(m,1H),1.34(s,3H),1.21(t,J=7.1Hz,3H),1.03(s,3H).GC-MS(EI,M + )m / z:185.

[0383] Step C: Under nitrogen protection, 1-2 (300 mg), 24-4 (378 mg), tris(dibenzylideneacetone)dipalladium(0) (112 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (95 mg), cesium carbonate (666 mg), triethylamine (1.12 mL), and toluene (30 mL) were added to a single-necked bottle in sequence; the reaction was carried out at 110°C for 4 h. The mixture was cooled to room temperature, diluted with EA (30 mL), and 30 mL of water was added. The organic phase was separated, and the aqueous phase was extracted with EA. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was purified by silica gel column chromatography (DCM / MeOH) to give 24-5 (250 mg). MS (ESI+, [M+H] + )m / z:472.25.

[0384] Step D: Under nitrogen protection and ice bath, 24-5 (250 mg) and THF (10 mL) were added to a single-necked flask in sequence, and a solution of lithium aluminum hydride in tetrahydrofuran (0.263 mL, 2.5 M) was added dropwise. After completion of the addition, 10 mL of 0.1 M sodium hydroxide solution was added to quench the mixture, followed by extraction with EA. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give compound 24 (120 mg). MS (ESI+, [M+H] + )m / z:430.22.

[0385] Step E: Compound 24 (120 mg) was purified by silica gel column chromatography and then subjected to chiral separation (YMC high pressure preparative chromatography: CHIRALART Cellulose-SC column, ethanol / n-hexane). The first eluting peak was compound 24_A (50 mg) and the second eluting peak was compound 24_B (50 mg).

[0386] Compound 24_A: 1 H NMR (500MHz, DMSO-d6) δ7.97(d,J=8.9Hz,1H),7.90(d,J=8.3Hz,1H),7.84(d,J=2. 0Hz,1H),7.74(d,J=8.7Hz,2H),7.61-7.56(m,1H),7.32-7.30(m,1H),7.29-7.23(m ,1H),7.20-7.16(m,2H),4.74(t,J=4.9Hz,1H),3.68-3.51(m,2H),2.49-2.43(m,1 H),2.43-2.35(m,1H),2.35-2.28(m,1H),1.28(s,3H),1.18(s,3H).MS(ESI+,[M+H] + )m / z:430.26.

[0387] Compound 24_B: 1H NMR (500MHz, DMSO-d6) δ7.97(d,J=8.8Hz,1H),7.90(d,J=8.3Hz,1H),7.84(d,J=2.0Hz,1 H),7.74(d,J=8.7Hz,2H),7.61-7.56(m,1H),7.33-7.30(m,1H),7.29-7.23(m,1H),7.18 (d,J=8.6Hz,2H),4.74(t,J=4.9Hz,1H),3.69-3.60(m,1H),3.60-3.51(m,1H),2.49-2.4 3(m,1H),2.42-2.35(m,1H),2.35-2.28(m,1H),1.28(s,3H),1.18(s,3H).MS(ESI+,[M+H] + )m / z:430.24.

[0388] Example 25 (25_A and 25_B)

[0389] Step A: To a single-necked flask, add 25-1 (500 mg) and dissolve in methanol (15 mL). Add thionyl chloride (0.9 mL) under ice-cooling conditions, then heat to 60°C and stir for 5 h. After the reaction is complete, stop the reaction, add 20 mL of toluene, and spin-dry the solvent to obtain 25-2 (700 mg). 1 HNMR(500MHz,DMSO-d6)δ3.65(s,3H),3.61(s,3H),3.51-3.42(m,1H),2.77-2.68(m,2H),2.50-2.36(m,2H),1.95-1.76(m,2H).

[0390] Step B: To a single-necked flask, add 25-2 (700 mg), methanol (15 mL), and triethylamine (1.5 mL) in sequence. Heat under reflux at 65°C with stirring for 3 h. After the reaction is complete, stop the reaction, spin dry the solvent, add ethyl acetate (30 mL), filter, and spin dry the filtrate again to obtain 25-3 (470 mg). 1 HNMR (500MHz, DMSO-d6) δ7.63 (s, 1H), 3.87-3.80 (m, 1H), 3.60 (s, 3H), 2.49 (d, J = 3.4Hz, 2H), 2.22-2.05 (m, 3H), 1.69-1.61 (m, 1H).

[0391] Step C: Referring to the synthesis of Example 1, in step B, 25-3 was substituted for 4-hydroxy-2-pyrrolidone, and the resulting crude product was purified by silica gel column chromatography to obtain 25-4 (215 mg). MS (ESI+, [M+H]+ )m / z:444.21.

[0392] Step D: To a single-necked flask, add 25-4 (180 mg), methanol (6 mL), tetrahydrofuran (2 mL) and a solution of sodium hydroxide (640 mg) in water (8 mL) in sequence, and heat with stirring at 50°C for 2 h. After the reaction is complete, stop heating, cool to room temperature, add 20 mL of water, and adjust the solution to pH 4 with 1N aqueous hydrochloric acid. Extract with ethyl acetate, combine the organic phases, wash with saturated brine, and dry over anhydrous sodium sulfate. Filter with suction, and the filtrate is spin-dried to obtain 25-5 (170 mg). MS (ESI+, [M+H] + )m / z:430.24.

[0393] Step E: To a single-necked flask, 25-5 (200 mg), tetrahydrofuran (10 mL), and N-methylmorpholine (52 mg) were added sequentially. Isobutyl chloroformate (70 mg) was added under ice-bath conditions. After stirring at room temperature for 1.5 h, sodium borohydride (106 mg) was added and stirring was continued at room temperature for 12 h. After the reaction was completed, the reaction was stopped and 30 mL of water was added. The reaction was quenched by adding 1N aqueous hydrochloric acid (2 mL). The organic phases were extracted with ethyl acetate, and the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography to obtain compound 25 (100 mg).

[0394] 1 H NMR(500MHz,DMSO-d6)δ8.09(d,J=2.1Hz,1H),7.94(d,J=9.1Hz,1H),7.81(d ,J=8.3Hz,1H),7.77-7.72(m,3H),7.55(t,J=7.9Hz,1H),7.20-7.14(m,3H), 4.58-4.50(m,2H),3.53-3.44(m,2H),2.68-2.57(m,1H),2.49-2.40(m,1H), 2.38-2.26(m,1H),1.95-1.86(m,1H),1.86-1.77(m,1H),1.60-1.50(m,1H). HRMS (ESI+, [M+H] + )m / z:416.1477.

[0395] Step F: Compound 25 (90 mg) was subjected to high pressure preparative liquid separation (CHIRALART Amylose-SA column; n-hexane:ethanol = 70:30). The first eluting peak was compound 25_A (30 mg) and the second eluting peak was compound 25_B (40 mg).

[0396] Compound 25_A: 1H NMR(500MHz,DMSO-d6)δ8.08(d,J=2.1Hz,1H),7.94(d,J=9.1Hz,1H),7.81(d ,J=8.3Hz,1H),7.77-7.70(m,3H),7.55(t,J=7.9Hz,1H),7.21-7.12(m,3H), 4.57-4.50(m,2H),3.51-3.43(m,2H),2.66-2.57(m,1H),2.48-2.40(m,1H), 2.37-2.26(m,1H),1.94-1.87(m,1H),1.87-1.76(m,1H),1.60-1.50(m,1H). HRMS (ESI+, [M+H] + )m / z:416.1475.

[0397] Compound 25_B: 1 H NMR(500MHz,DMSO-d6)δ8.08(d,J=2.1Hz,1H),7.94(d,J=9.0Hz,1H),7.81(d ,J=8.2Hz,1H),7.79-7.67(m,3H),7.55(t,J=7.8Hz,1H),7.22-7.11(m,3H), 4.63-4.46(m,2H),3.53-3.43(m,2H),2.67-2.57(m,1H),2.48-2.40(m,1H), 2.38-2.24(m,1H),1.96-1.86(m,1H),1.86-1.75(m,1H),1.63-1.49(m,1H). HRMS (ESI+, [M+H] + )m / z:416.1478.

[0398] Example 26 (26_A and 26_B)

[0399] Step A: Referring to the synthesis of Example 1, in step B, 26-1 was used instead of 4-hydroxy-2-pyrrolidone to obtain compound 26 (130 mg).

[0400] 1H NMR(500MHz,DMSO-d6)δ8.12(d,J=2.2Hz,1H),7.95(d,J=9.1Hz,1H),7.87-7 .79(m,1H),7.82(d,J=8.3Hz,1H),7.78-7.69(m,2H),7.55(t,J=7.9Hz,1H),7 .22-7.12(m,3H),5.08(t,J=5.3Hz,1H),4.80-4.73(m,1H),4.55(t,J=8.6Hz, 1H),4.40-4.32(m,1H),3.69-3.57(m,1H),3.54-3.47(m,1H).MS(ESI+,[M+H] + )m / z:404.11.

[0401] Step B: Compound 26 was subjected to chiral separation (YMC high pressure preparative chromatography: CHIRALART Cellulose-SC column, ethanol / n-hexane). The first eluting peak was compound 26_A (58 mg), and the second eluting peak was compound 26_B (58 mg).

[0402] Compound 26_A: 1 H NMR (500MHz, DMSO-d6) δ8.12(d,J=2.3Hz,1H),7.95(d,J=9.1Hz,1H),7.90-7.79(m,2H),7.77-7.69(m,2H),7.55(t,J=7.9Hz,1H),7.22-7.11(m ,3H),5.08(t,J=5.3Hz,1H),4.80-4.73(m,1H),4.55(t,J=8.6Hz,1H),4 .40-4.33(m,1H),3.65-3.57(m,1H),3.54-3.46(m,1H).MS(ESI+,[M+H] + )m / z:404.13.

[0403] Compound 26_B: 1H NMR (500MHz, DMSO-d6) δ8.12(d,J=2.2Hz,1H),7.95(d,J=9.1Hz,1H),7.90-7.79(m,2H),7.77-7.69(m,2H),7.59-7.52(m,1H),7.20-7.12(m, 3H),5.08(t,J=5.3Hz,1H),4.80-4.73(m,1H),4.55(t,J=8.6Hz,1H),4.40-4.34(m,1H),3.65-3.57(m,1H),3.54-3.46(m,1H).MS(ESI+,[M+H] + )m / z:404.09.

[0404] Example 27 (27_A and 27_B)

[0405] Step A: Under nitrogen, 27-1 (5.0 g), 27-2 (5.87 g), and NMP (30 mL) were added sequentially to a single-necked flask and heated to 120°C for 4 h. The reaction solution was cooled to room temperature and slowly poured into ice water (300 mL). The mixture was filtered, and the filter cake was washed with water, PE, and dried to afford compound 27-3 (8.4 g). MS (ESI+, [M+H]+) m / z: 264.08.

[0406] Step B: Under nitrogen, 27-3 (2.00 g), N,O-dimethylhydroxylamine hydrochloride (1.10 g), EDCI (2.18 g), DMAP (1.39 g), and DCM (30 mL) were added sequentially to a single-necked flask and allowed to react at room temperature for 3 h. 0.1 M hydrochloric acid (20 mL) was added to the reaction solution, and the organic phase was separated and washed with saturated sodium bicarbonate and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated. The crude product was purified by silica gel column chromatography to yield compound 27-4 (2.3 g). MS (ESI+, [M+H]+) m / z: 307.17.

[0407] Step C: Under nitrogen protection and ice bath, 27-4 (2.2 g) and 2-MeTHF (30 mL) were added to a three-necked flask in sequence, and methylmagnesium bromide (4.33 mL, 3 M tetrahydrofuran solution) was added dropwise. The mixture was stirred at 0°C for 60 min and reacted at room temperature for 2 h. 1 M hydrochloric acid (20 mL) was added at 0°C to quench the mixture. The organic phase was separated and washed with saturated sodium carbonate solution and saturated brine. The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was purified by silica gel column chromatography (PE / EA). Compound 27-5 (1.55 g) was obtained. MS (ESI+, [M+H] + )m / z:262.30

[0408] Step D: Under nitrogen protection and ice bath, 27-5 (425 mg) and methanol (10 mL) were added to a single-necked bottle, and sodium borohydride (73.8 mg) was added in batches. The mixture was stirred for 30 min and reacted at room temperature for 1 h. Saturated ammonium chloride was added to quench the reaction. The mixture was then concentrated under reduced pressure to remove most of the methanol, and water (10 mL) was added and extracted with EA. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 27-6 (0.4 g). MS (ESI+, [M+H] + )m / z:264.17

[0409] Step E: Under nitrogen protection, 27-6 (0.4 g) and TFA (3 mL) were added to a microwave tube, placed in a microwave reactor, heated to 90°C for 60 min, and water (0.5 mL) was added, followed by concentration and drying to obtain compound 27-7 (0.3 g).

[0410] Step F: Referring to the synthesis of Example 1, in step B, 27-7 was substituted for 4-hydroxy-2-pyrrolidone to obtain compound 27 (90 mg). MS (ESI+, [M+H] + )m / z:416.29.

[0411] Step G: Compound 27 (90 mg) was subjected to silica gel column chromatography (eluent: DCM:MeOH=30:1) to separate the chirality. The first eluting peak was compound 27_A (36 mg) and the second eluting peak was compound 27_B (38 mg).

[0412] Compound 27_A: 1 H NMR(500MHz,DMSO-d6)δ8.14-8.08(m,2H),7.94-7.89(m,1H),7.82(d,J=8.3 Hz,1H),7.73(d,J=8.5Hz,2H),7.53(t,J=7.9Hz,1H),7.17-7.11(m,3H),4.8 5(d,J=5.0Hz,1H),4.05-3.93(m,1H),3.91-3.81(m,1H),3.72-3.63(m,1H), 2.63-2.53(m,1H),2.47-2.36(m,2H),1.13(d,J=6.3Hz,3H).MS(ESI+,[M+H] + )m / z:416.27.

[0413] Compound 27_B: 1H NMR (500MHz, DMSO-d6) δ8.14-8.08(m,2H),7.91(d,J=9.7Hz,1H),7.81(d,J=8.3Hz,1H),7.73(d,J=8.6Hz,2H),7.53(t,J=7.9Hz,1H),7.14(d,J=8. 1Hz,3H),4.81(d,J=4.8Hz,1H),4.02-3.91(m,1H),3.80-3.66(m,2H),2. 65-2.52(m,2H),2.49-2.40(m,1H),1.11(d,J=6.2Hz,3H).MS(ESI+,[M+H] + )m / z:416.31.

[0414] Example 28 (28_A and 28_B)

[0415] Step A: Glycine methyl ester hydrochloride (6.70 g), acetonitrile (100 mL), 4-methoxybenzyl chloride (18.39 g), and DIPEA (20.69 g) were added sequentially to an eggplant-shaped flask and reacted at 110°C overnight. Water (150 mL) was added to the reaction solution and extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE / EA) to obtain compound 28-1 (17 g). MS (ESI+, [M+H] + )m / z:330.14.

[0416] Step B: 28-1 (17 g), tetrahydrofuran (20 mL), methanol (20 mL), water (20 mL) and NaOH (10.32 g) were added to an eggplant-shaped flask in sequence. The mixture was stirred at room temperature for 2 h, and then the pH was adjusted to 6-7 with 6 M hydrochloric acid. The mixture was filtered, and the filter cake was washed with petroleum ether and dried under vacuum to obtain compound 28-2 (16 g). MS (ESI+, [M+H] + )m / z:316.10.

[0417] Step C: Compound 28-2 (16 g), dichloromethane (100 mL), N,O-dimethylhydroxylamine hydrochloride (3.72 g), HATU (28.9 g), and DIPEA (19.67 g) were added to an eggplant-shaped flask in sequence and stirred at room temperature for 4 h. The reaction solution was concentrated and purified by silica gel column chromatography (PE / EA) to obtain compound 28-3 (12 g). MS (ESI+, [M+H] + )m / z:359.21.

[0418] Step D: 28-3 (10 g) and tetrahydrofuran (10 mL) were added to an eggplant-shaped flask in sequence. After N2 protection, the mixture was stirred in an ice bath for 5 minutes. Then, a solution of methylmagnesium bromide in diethyl ether (3 mol / L, 13 mL) was added and the reaction was continued in an ice bath for 1 hour. Water (150 mL) was added to the reaction solution and extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: PE / EA) to obtain compound 28-4 (7.2 g). MS (ESI+, [M+H] + )m / z:314.14.

[0419] Step E: Ethyl acetate (1.23 g) and tetrahydrofuran (30 mL) were added to a two-necked flask in sequence. After N2 protection, the mixture was placed in a -78°C low-temperature tank and stirred for 10 min. LDA (2M tetrahydrofuran solution, 7 mL) was added. After stirring for 10 min, a solution of 28-4 (3 g) in tetrahydrofuran (30 mL) was added. After 15 min, the reaction solution was brought to room temperature and the reaction was continued with stirring. After 30 min, water (150 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 28-5 (2.7 g). MS (ESI+, [M+H] + )m / z:402.30.

[0420] Step F: Compound 28-5 (50 mg), ethanol (20 mL), and palladium carbon (10% wt, 50 mg) were added to an eggplant-shaped flask in sequence. After hydrogen replacement, the temperature was raised to 80°C and the reaction was allowed to react for 1 h. The reaction solution was filtered and dried to give compound 28-6 (45 mg). MS (ESI+, [M+H] + )m / z:162.11.

[0421] Step G: Add 28-6 (45 mg), water (2 mL) and concentrated ammonia (2 mL) to an eggplant-shaped bottle in sequence and stir at room temperature for 1 h. The reaction solution was directly spin-dried to give compound 28-7 (30 mg). MS (ESI+, [M+H] + )m / z:116.07.

[0422] Step H: Referring to the synthesis of Example 1, in step B, 28-7 was used instead of 4-hydroxy-2-pyrrolidone to obtain compound 28 (40 mg).

[0423] 1H NMR (500MHz, DMSO-d6) δ8.10-8.03(m,2H),7.95-7.89(m,1H),7.81(d,J=8.3Hz,1H),7.79-7.70(m,2H),7.53(t,J=7.9Hz,1H),7.19-7.11(m, 3H),5.27(s,1H),3.96(d,J=10.0Hz,1H),3.77(d,J=10.0Hz,1H),2.74(d,J=16.7Hz,1H),2.48(d,J=16.1Hz,1H),1.42(s,3H).MS(ESI+,[M+H] + )m / z:402.13.

[0424] Step I: Compound 28 (170 mg) was subjected to high pressure preparative liquid separation (REFLECT I-Amylose A column; ethanol:n-hexane = 22:78). The first eluting peak was compound 28_A (40 mg) and the last eluting peak was compound 28_B (60 mg).

[0425] Compound 28_A: 1 H NMR (500MHz, DMSO-d6) δ8.12-8.05(m,2H),7.92(d,J=9.0Hz,1H),7.81(d,J=8.3Hz,1H),7.75-7.69(m,2H),7.53(t,J=7.9Hz,1H),7.19-7.10 (m,3H),5.28(s,1H),3.96(d,J=10.0Hz,1H),3.77(d,J=10.0Hz,1H),2.74(d,J=16.7Hz,1H),2.50-2.44(m,1H),1.42(s,3H).MS(ESI+,[M+H] + )m / z:402.13.

[0426] Compound 28_B: 1 H NMR (500MHz, DMSO-d6) δ8.10-8.05(m,2H),7.94-7.89(m,1H),7.81(d,J=8.3Hz,1H),7.77-7.70(m,2H),7.57-7.51(m,1H),7.18-7.11(m, 3H),5.27(s,1H),3.96(d,J=10.0Hz,1H),3.77(d,J=10.1Hz,1H),2.74(d,J=16.6Hz,1H),2.50-2.44(m,1H),1.42(s,3H).MS(ESI+,[M+H] +)m / z:402.13.

[0427] Example 29 (29_A and 29_B)

[0428] Step A: Referring to the synthesis of Example 1, in step B, 5-hydroxymethyl-1,3-oxazolidin-2-one was used instead of 4-hydroxy-2-pyrrolidone to obtain compound 29 (220 mg). HRMS (ESI+, [M+H] + )m / z:404.1113.

[0429] Step B: Compound 29 (220 mg) was separated by high pressure preparative liquid chromatography (REFLECT I-Amylose A column; ethanol:n-hexane = 40:60). The first eluting peak was compound 29_A (46 mg) and the second eluting peak was compound 29_B (96 mg).

[0430] Compound 29_A: 1 H NMR (500MHz, DMSO-d6) δ8.05 (dd, J=9.2, 2.2Hz, 1H), 7.99 (d, J=2.3Hz, 1H), 7. 95(d,J=9.3Hz,1H),7.81(d,J=8.3Hz,1H),7.76-7.69(m,2H),7.61-7.51(m,1 H),7.18-7.08(m,3H),5.27-5.17(m,1H),4.74-4.79(m,1H),4.22(t,J=8.9Hz ,1H),4.12-3.95(m,1H),3.70-3.74(m,1H),3.58-3.63(m,1H).MS(ESI+,[M+H] + )m / z:404.11.

[0431] Compound 29_B: 1 H NMR (500MHz, DMSO-d6) δ8.05 (dd, J=9.2, 2.2Hz, 1H), 7.99 (d, J=2.3Hz, 1H), 7. 95(d,J=9.3Hz,1H),7.81(d,J=8.3Hz,1H),7.76-7.69(m,2H),7.61-7.51(m,1 H),7.18-7.08(m,3H),5.27-5.17(m,1H),4.74-4.79(m,1H),4.22(t,J=8.9Hz ,1H),4.12-3.95(m,1H),3.70-3.74(m,1H),3.58-3.63(m,1H).MS(ESI+,[M+H] + )m / z:404.11.

[0432] Example 30

[0433] Step A: DMF (15 mL), 7-bromo-4-chloro-2-methylquinazoline (500 mg), 4-trifluoromethylphenol (472 mg) and cesium carbonate (1.90 g) were added to an eggplant-shaped flask in sequence and the temperature was raised to 80°C for 3 h. Water (150 mL) was added to the reaction solution and extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE / EA) to obtain compound 30-2 (650 mg). MS (ESI+, [M+H] + )m / z:383.09.

[0434] Step B: To a single-necked flask were added 30-2 (200 mg), 4-hydroxymethyl-2-pyrrolidone (72 mg), Pd2(dba)3 (10 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (18 mg), cesium carbonate (510 mg), and 1,4-dioxane (20 mL) in sequence. The mixture was heated to 110°C under nitrogen for 4 h. The mixture was cooled to room temperature, diluted with EA (30 mL), and 30 mL of water was added. The organic phase was separated, and the aqueous phase was extracted with EA. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was purified by silica gel column chromatography to obtain compound 30 (110 mg).

[0435] 1 H NMR (500MHz, DMSO-d6) δ8.35-8.23(m,2H),7.99(d,J=2.1Hz,1H),7.88(d,J=8.5Hz,2H),7.61(d,J=8.4Hz,2H),4.91(t,J=5.3Hz,1H), 4.12-4.05(m,1H),3.81-3.76(m,1H),3.56-3.44(m,2H),2.77-2.70(m,1H),2.66-2.55(m,1H),2.49(s,3H),2.47-2.38(m,1H).MS(ESI + ,[M+H] + )m / z:418.26.

[0436] Example 31

[0437] Step A: Referring to step A of Example 30, 7-bromo-4-chloro-quinoline was substituted for 7-bromo-4-chloro-2-methylquinazoline to obtain compound 31-2 (670 mg). MS (ESI+, [M+H]+ )m / z:368.03.

[0438] Step B: Referring to the process of step B of Example 30, compound 31-2 was used to replace compound 30-2 to prepare compound 31 (70 mg).

[0439] 1 H NMR (500MHz, DMSO-d6) δ8.74(d,J=5.1Hz,1H),8.27-8.20(m,2H),8.14(s,1H),7.88(d,J=8.6Hz,2H),7.48(d,J=8.4Hz,2H),6.77(d,J=5.1Hz,1H) ,4.91(t,J=5.3Hz,1H),4.12-4.05(m,1H),3.84-3.75(m,1H),3.56-3.45 (m,2H),2.75-2.67(m,1H),2.67-2.55(m,1H),2.44-2.37(m,1H).MS(ESI + ,[M+H] + )m / z:403.27.

[0440] Example 32

[0441] Step A: To an eggplant-shaped flask, 32-1 (5 g) and dimethyl ethylphosphinoacetate (15.07 g) were added sequentially. The mixture was stirred on ice for 10 min, followed by the addition of a solution of KOH (53 g) in water (63 mL). After 30 min, the reaction mixture was brought to room temperature and stirred overnight. The reaction mixture was extracted with DCM, and the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to afford compound 32-2 (7.2 g), which was used directly in the next reaction.

[0442] Step B: Add 32-2 (1 g) and tetrahydrofuran (25 mL) to an eggplant-shaped flask in sequence, place in a -10°C low-temperature tank and stir for 10 min, then add nitromethane (0.46 g) and TBAF (1 M tetrahydrofuran solution, 7.5 mL) in sequence, and continue the reaction at low temperature for 4 h. Add 100 mL of water to the reaction solution, extract with EA, combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate to obtain compound 32-3 (1.07 g). GC-MS (EI, M + )m / z:261.

[0443] Step C: To an eggplant-shaped flask were added 32-3 (1.07 g), methanol (50 mL), Pd(OH)2 (0.58 g), and ammonium formate (1.29 g) in sequence. The mixture was heated to 80°C and refluxed overnight under a hydrogen atmosphere. The reaction mixture was cooled to room temperature, filtered, and the filtrate was added with 100 mL of water and extracted with EA. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to afford compound 32-4 (750 mg), which was used directly in the next step.

[0444] Step D: Referring to step B of Example 30, compound 1-2 was substituted for 30-2, and compound 32-4 was substituted for 4-hydroxymethyl-2-pyrrolidone to obtain compound 32-5 (80 mg). MS (ESI + ,[M+H] + )m / z:472.25.

[0445] Step E: To an eggplant-shaped flask, 32-5 (80 mg) and a 4 M solution of dioxane hydrochloride (4 mL) were added sequentially and stirred at room temperature for 2 h. The reaction solution was concentrated and the resulting crude product was separated by high-pressure preparative liquid chromatography (Ultimate Polar RP8 column, water:acetonitrile = 20:80) to afford compound 32 (40 mg).

[0446] 1 H NMR (500MHz, DMSO-d6) δ8.14-8.07(m,2H),7.91(d,J=8.9Hz,1H),7.85-7.79(m,1H),7.73(d,J=8.7Hz,2H),7.53(t,J=8.0Hz,1H),7.18 -7.11(m,3H),4.95-4.90(m,1H),4.69-4.61(m,1H),4.03-3.88(m,2H),3.57-3.49(m,1H),3.47-3.35(m,2H),2.68-2.52(m,3H).MS(ESI + ,[M+H] + )m / z:432.26.

[0447] Example 33

[0448] Step A: Under nitrogen protection and an ice bath, add p-trifluoromethylphenol (399 mg), THF (10 mL), and potassium tert-butoxide (323 mg) to a single-necked flask, stir for 10 min, add 33-1 (500 mg), and react at 0°C for 3 h. Add EA (10 mL) and adjust the pH to neutral with 0.1 M hydrochloric acid. Then separate the organic phase, extract the aqueous phase with EA, combine the organic phases, wash with saturated sodium bicarbonate solution, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate. The resulting crude product is purified by silica gel column chromatography (PE / EA) to give compound 33-2 (0.6 g). MS (ESI+, [M+H] + )m / z:369.10.

[0449] Step B: Referring to the reaction process of step B in Example 30, compound 33-2 was used to replace compound 30-2 to obtain compound 33 (130 mg).

[0450] 1 H NMR(500MHz, DMSO-d6)δ8.70(s,1H),8.41-8.32(m,2H),8.09(d,J=2.1Hz,1H),7.93-7.87(m,2H),7.66-7.60(m,2H),4.92(t,J=5.3Hz, 1H),4.15-4.06(m,1H),3.88-3.76(m,1H),3.56-3.45(m,2H),2.79-2.70(m,1H),2.67-2.56(m,1H),2.49-2.38(m,1H).MS(ESI+,[M+H] + )m / z:404.23.

[0451] Example 34 (34_A and 34_B)

[0452] Step A: To a two-necked flask, 34-1 (5.0 g), THF (50 mL), H2O (50 mL) and sodium carbonate (7.06 g) were added in sequence. Under N2 protection, the mixture was stirred at room temperature for 0.5 h. The temperature was then lowered to 0°C and a solution of benzyl chloroformate (6.82 g) in THF (20 mL) was added dropwise. After the addition, the mixture was stirred at room temperature overnight. After the reaction was completed, the reaction solution was poured into 100 mL of water and concentrated under reduced pressure to remove THF. The mixture was extracted with EA, and the organic phase was discarded. The aqueous phase was placed in an ice bath and adjusted to pH 1-2 with 2M hydrochloric acid. The filter cake was filtered and washed with water. The intermediate 34-2 (6.5 g) was obtained by drying under reduced pressure. MS (ESI+, [M+Na] + )m / z:289.04.

[0453] Step B: 34-2 (6.5 g), DMF (100 mL) and sodium bicarbonate (4.1 g) were added to a two-necked flask in sequence. Under N2 protection, the mixture was cooled to 0°C and iodomethane (8.66 g) was added dropwise. After the addition, the mixture was stirred at room temperature overnight. After the reaction, the reaction solution was poured into 100 mL of ice water and extracted with EA. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was added to a mixed solvent (PE / EA) and slurried to obtain intermediate 34-3 (4.0 g). MS (ESI+, [M+Na] + )m / z:303.05.

[0454] Step C: 34-3 (4.0 g), THF (200 mL) and 1,8-diazabicyclo[5.4.0]undec-7-ene (4.34 g) were added to a single-necked flask in sequence. The mixture was cooled to 0°C and iodophenyldiacetic acid (9.2 g) was added. After the addition was complete, the mixture was stirred at 0°C for 20 minutes. After the reaction was completed, the reaction solution was poured into 100 mL of ice water and extracted with EA. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (MeOH / DCM) to obtain intermediate 34-4 (1.58 g). MS (ESI+, [M+H] + )m / z:278.95.

[0455] Step D: 1-2 (400 mg), 34-4 (455 mg), Pd(OAc)2 (36 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (104 mg), cesium carbonate (1.0 g) and 1,4-dioxane (50 mL) were added to a single-necked bottle in sequence. The mixture was heated to 110°C and refluxed for 1 h under N2 protection. After the reaction, 100 mL of water was added, and the mixture was extracted with EA. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (PE / EA) to obtain intermediate 34-5 (501 mg). MS (ESI+, [M+H] + )m / z:565.31.

[0456] Step E: 34-5 (500 mg), MeOH (20 mL), THF (10 mL) and Pd / C (10% wt, 95 mg) were added to a single-necked bottle in sequence. After the addition, H2 was replaced 5 times and the mixture was stirred at room temperature under H2 atmosphere overnight. After the reaction was completed, the mixture was directly filtered and the filtrate was concentrated to dryness under reduced pressure to obtain intermediate 34-6 (368 mg). MS (ESI-, [MH] - )m / z:429.36.

[0457] Step F: To a two-necked flask, 34-6 (170 mg) and DMF (5 mL) were added sequentially. Under N2 protection, the mixture was cooled to 0°C and sodium hydride (60% wt purity, 55 mg) was added portionwise. After 10 minutes, iodomethane (84 mg) was added dropwise. After the addition, the mixture was stirred at 0°C for 1 hour. After the reaction, the reaction solution was poured into 100 mL of ice-cold saturated ammonium chloride solution and extracted with EA. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent to obtain intermediate 34-7 (176 mg). MS (ESI-, [MH] - )m / z:443.21.

[0458] Step G: Referring to step B of Example 21, compound 34-7 was substituted for compound 21-1 to obtain compound 34 (150 mg). MS (ESI+, [M+H] + )m / z:417.24.

[0459] Step H: Compound 34 (150 mg) was subjected to high pressure preparative liquid separation (REFLECT I-Amylose A column; ethanol:n-hexane = 30:70). The first eluting peak was compound 34_A (58 mg) and the second eluting peak was compound 34_B (68 mg).

[0460] Compound 34_A: 1 H NMR (500MHz, DMSO-d6) δ8.22-8.20(m,1H),7.86-7.81(m,2H),7.74-7.71(m,3H),7.48(t,J=7.8Hz,1H),7.13(d,J=8.7Hz,2H),7. 05(d,J=7.4Hz,1H),5.00(t,J=5.5Hz,1H),4.05-3.97(m,1H),3.74-3.65(m,3H),3.58-3.54(m,1H),2.82(s,3H).MS(ESI+,[M+H] + )m / z:417.27.

[0461] Compound 34_B: 1H NMR (500MHz, DMSO-d6) δ8.22-8.19(m,1H),7.86-7.81(m,2H),7.74-7.71(m,3H),7.48(t,J=7.8Hz,1H),7.13(d,J=8.6Hz,2H),7. 05(d,J=7.5Hz,1H),4.99(t,J=5.5Hz,1H),4.04-3.97(m,1H),3.74-3.65(m,3H),3.58-3.54(m,1H),2.82(s,3H).MS(ESI+,[M+H] + )m / z:417.31.

[0462] Example 35 (35_A and 35_B)

[0463] Step A: Referring to step B of Example 21, compound 34-6 was substituted for compound 21-1 to obtain compound 35 (130 mg). MS (ESI+, [M+H] + )m / z:403.26.

[0464] Step B: Compound 35 (130 mg) was subjected to high pressure preparative liquid separation (REFLECT I-Amylose A column; ethanol:n-hexane = 30:70). The first eluting peak was compound 35_A (60 mg) and the second eluting peak was compound 35_B (62 mg).

[0465] Compound 35_A: 1 H NMR (500MHz, DMSO-d6) δ8.19-8.17(m,1H),7.85-7.82(m,2H),7.75-7.71(m,3H),7.48(t,J=7.9Hz,1H),7.24(s,1H),7.13(d,J=8 .5Hz,2H),7.05(d,J=7.5Hz,1H),4.99(t,J=5.5Hz,1H),4.05-4.01(m,1H),3.78-3.73(m,2H),3.49-3.40(m,2H).MS(ESI+,[M+H] + )m / z:403.30.

[0466] Compound 35_B: 1H NMR (500MHz, DMSO-d6) δ8.19-8.17(m,1H),7.85-7.81(m,2H),7.75-7.71(m,3H),7.48(t,J=7.8Hz,1H),7.24(s,1H),7.13(d,J =8.7Hz,2H),7.06-7.05(m,1H),4.98(t,J=5.5Hz,1H),4.05-4.01(m,1H),3.79-3.73(m,2H),3.49-3.40(m,2H).MS(ESI+,[M+H] + )m / z:403.26.

[0467] Example 36

[0468] Step A: To a single-necked flask, 34-4 (600 mg), THF (20 mL), triethylamine (655 mg), di-tert-butyl dicarbonate (710 mg) and 4-dimethylaminopyridine (26 mg) were added in sequence. Under N2 protection, the mixture was stirred at room temperature for 5 h. After the reaction, the reaction solution was poured into 100 mL of water and extracted with EA. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was purified by silica gel column chromatography (MeOH / DCM) to obtain intermediate 36-1 (770 mg). MS (ESI+, [M+Na] + )m / z:401.27.

[0469] Step B: 36-1 (770 mg), MeOH (20 mL) and Pd / C (10% wt purity, 217 mg) were added to a single-necked bottle in sequence. After the addition, H2 was replaced 5 times and the mixture was stirred at room temperature under H2 atmosphere overnight. After the reaction was completed, the mixture was directly filtered and the filtrate was concentrated to dryness under reduced pressure to obtain intermediate 36-2 (510 mg). MS (ESI+, [M+H] + )m / z:245.05.

[0470] Step C: Referring to step D of Example 34, compound 36-2 was substituted for compound 34-4 to obtain intermediate 36-3 (234 mg). MS (ESI+, [M+Na] + )m / z:553.30.

[0471] Step D: To a single-necked flask, 36-3 (234 mg) and 4M hydrogen chloride-dioxane solution (5 mL) were added sequentially and stirred at room temperature for 0.5 h. After the reaction, the reaction solution was slowly added dropwise to a saturated sodium bicarbonate solution (100 mL) under an ice bath. The mixture was extracted with EA, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The resulting crude product was purified by silica gel column chromatography to obtain intermediate 36-4 (184 mg). MS (ESI+, [M+H] + )m / z:431.00.

[0472] Step E: Referring to step B of Example 21, compound 36-4 was used to replace compound 21-1 to obtain compound 36 (67 mg).

[0473] 1 H NMR (500MHz, DMSO-d6) δ8.00(d,J=2.0Hz,1H),7.95-7.93(m,1H),7.85(d,J=9.2Hz,1H),7.74-7.72(m,3H),7.49(t,J=7.9Hz,1H),7.14(d,J=8 .6Hz,2H),7.08(d,J=7.5Hz,1H),7.00(s,1H),4.96(t,J=5.6Hz,1H),4.59-4.54(m,1H),3.57-3.49(m,3H),3.38-3.35(m,1H).MS(ESI+,[M+H] + )m / z:403.25.

[0474] Example 37

[0475] Step A: Referring to step F of Example 34, intermediate 36-4 was substituted for intermediate 34-6 to obtain intermediate 37-1 (76 mg). MS (ESI+, [M+H] + )m / z:445.28.

[0476] Step B: Referring to step B of Example 21, intermediate 37-1 was used to replace intermediate 21-1 to obtain compound 37 (60 mg).

[0477] 1H NMR (500MHz, DMSO-d6) δ7.99(d,J=1.7Hz,1H),7.95-7.93(m,1H),7.85(d,J=9.2Hz,1H),7.74-7.72(m,3H),7.51-7.48(m,1H),7.14(d,J=8. 6Hz,2H),7.09(d,J=7.5Hz,1H),4.97(t,J=5.5Hz,1H),4.53-4.49(m,1H),3.60-3.48(m,3H),3.43-3.40(m,1H),2.79(s,3H).MS(ESI+,[M+H] + )m / z:417.26.

[0478] Example 38

[0479] Step A: Add 38-1 (1 g) and THF (20 mL) to a two-necked flask. Under N2 protection, 1M lithium hexamethyldisilazide (17.5 mL) was slowly added dropwise at -78°C, and the mixture was stirred at -20°C for 1 hour. Benzyl chloromethyl ether (1.15 mL) was slowly added dropwise at -78°C, and the mixture was stirred at -20°C for 2 hours. After the reaction, 20 mL of saturated aqueous ammonium chloride solution was added, and the mixture was extracted with dichloromethane. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (DCM / MeOH) to obtain compound 38-2 (1.2 g). MS (ESI+, [M+H] + )m / z:264.12.

[0480] Step B: Referring to the synthesis of Example 1, in step B, 38-2 was substituted for 4-hydroxy-2-pyrrolidone to obtain compound 38-3 (220 mg). MS (ESI+, [M+H] + )m / z:550.18.

[0481] Step C: 38-3 (220 mg), 10% Pd / C (42.6 mg), and MeOH (20 mL) were added to a round-bottom flask in sequence. The reaction was stirred at room temperature under H2 for 16 hours. After the reaction was completed, the filtrate was filtered and concentrated to dryness under reduced pressure to obtain 38-4 (120 mg). MS (ESI+, [M+H] + )m / z:460.18.

[0482] Step D: 38-4 (120 mg), lithium borohydride (8.53 mg), and THF (20 mL) were added sequentially to a round-bottom flask. The mixture was stirred at room temperature for 16 hours. After the reaction was completed, 20 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness. The crude product was purified by silica gel column chromatography to obtain compound 38 (83 mg).

[0483] 1 H NMR (500MHz, DMSO-d6) δ7.95(d,J=8.9Hz,1H),7.89(d,J=1.9Hz,1H),7.83(d,J=8.3Hz,1H),7.79-7.67(m,2H),7.58(t,J=7.9Hz ,1H),7.41(m,1H),7.26(m,1H),7.17(s,2H),5.05(t,J=5.0Hz,2H),3.31-3.24(m,4H),2.42(m,2H),2.17(m,2H).MS(ESI+,[M+H] + )m / z:432.14.

[0484] Example 39 (39_A and 39_B)

[0485] Step A: 1-1 (0.29 g), 4-fluorophenylsulfur pentafluoride (0.29 g), cesium carbonate (1.27 g) and DMF (10 mL) were added to a microwave tube in sequence and heated to 120°C for 2 h. After the reaction, 100 mL of water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE / EA) to obtain compound 39-1 (0.51 g). MS (ESI-, [MH] - )m / z:423.00.

[0486] Step B: Referring to step B of Example 38, compound 39-1 was substituted for 1-2, and 4-hydroxymethyl-2-pyrrolidone was substituted for 38-2 to obtain compound 39 (238 mg). MS (ESI+, [M+H] + )m / z:460.21.

[0487] Step C: Compound 39 (238 mg) was separated by high pressure preparative liquid chromatography (REFLECT I-Amylose A column; ethanol:n-hexane = 30:70). The first eluting peak was compound 39_A (97 mg) and the second eluting peak was compound 39_B (104 mg).

[0488] Compound 39_A: 1 H NMR (500MHz, DMSO-d6) δ8.11-8.08(m,2H),7.90-7.88(m,3H),7.84(d,J=8. 3Hz,1H),7.56-7.53(m,1H),7.19(d,J=7.5Hz,1H),7.11(d,J=9.0Hz,2H),4 .90(t,J=5.3Hz,1H),4.05-4.01(m,1H),3.78-3.75(m,1H),3.53-3.44(m,2 H),2.69-2.61(m,1H),2.60-2.54(m,1H),2.39-2.34(m,1H).MS(ESI+,[M+H] + )m / z:460.10.

[0489] Compound 39_B: 1 H NMR (500MHz, DMSO-d6) δ8.12-8.08(m,2H),7.91-7.88(m,3H),7.84(d,J=8. 3Hz,1H),7.56-7.53(m,1H),7.20(d,J=7.5Hz,1H),7.11(d,J=9.1Hz,2H),4 .90(t,J=5.3Hz,1H),4.05-4.01(m,1H),3.78-3.75(m,1H),3.53-3.44(m,2 H),2.69-2.61(m,1H),2.60-2.55(m,1H),2.39-2.35(m,1H).MS(ESI+,[M+H] + )m / z:460.21.

[0490] Example 40

[0491] Step A: Benzyl glycidyl ether (2.50 g), dichloromethane (35 mL), benzylamine (1.47 g), and lithium bis(trifluoromethanesulfonyl imide) (0.44 g) were added to a reaction flask in sequence and reacted at room temperature overnight. The reaction solution was concentrated to dryness under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (DCM / MeOH) to obtain compound 40-1 (1.70 g). MS (ESI+, [M+H] + )m / z:272.31.

[0492] Step B: Compound 40-1 (3.00 g), dichloromethane (30 mL), triethylamine (3.36 g), and methanesulfonic anhydride (5.78 g) were added to the reaction flask in sequence and reacted at room temperature for 20 minutes. The reaction solution was quenched by adding saturated aqueous sodium bicarbonate solution (30 mL), and the resulting mixture was extracted with ethyl acetate. The organic layers were combined and purified by silica gel column chromatography (PE / EA) to obtain compound 40-2 (2.90 g). HRMS (ESI+, [M+H] + )m / z:428.1210.

[0493] Step C: 40-2 (2.70 g) and tetrahydrofuran (78 mL) were added to the reaction flask in sequence. After N2 protection, the mixture was stirred at -78°C for 10 min, and then n-butyl lithium (1.6 M tetrahydrofuran solution, 9.87 mL) was added. After the addition was complete, the reaction solution was moved to room temperature and reacted for 16 hours. The reaction solution was quenched by adding saturated aqueous ammonium chloride (100 mL). The resulting mixture was extracted with ethyl acetate, and the organic layers were combined and purified by silica gel column chromatography (PE / EA) to obtain compound 40-3 (0.35 g). MS (ESI+, [M+H] + )m / z:332.25.

[0494] Step D: 40-3 (0.22 g), ethanol (2 mL), and palladium carbon (1.41 g) were added to the reaction flask in sequence. After hydrogen replacement three times, the mixture was heated to 80°C and reacted for 17 hours. The reaction solution was filtered and the filtrate was concentrated to dryness under reduced pressure to obtain compound 40-4 (0.16 g). HRMS (ESI+, [M+H] + )m / z:242.0852.

[0495] Step E: 40-4 (0.16 g), ethanol (2 mL), and palladium carbon (1.41 g) were added to the reaction flask in sequence. After hydrogen replacement three times, the mixture was heated to 80°C for 6.5 hours and then transferred to room temperature for 16 hours. The reaction solution was filtered and the filtrate was concentrated to dryness under reduced pressure to obtain compound 40-5 (0.10 g). HRMS (ESI+, [M+H] + )m / z:152.0365.

[0496] Step F: To a reaction flask were added 1-2 (0.25 g), 40-5 (0.10 g), cesium carbonate (0.67 g), allylpalladium(II) chloride dimer (12.3 mg), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (28.9 mg), and 1,4-dioxane (2 mL) in sequence. The atmosphere was purged with nitrogen three times and heated to 110°C for 2.5 hours. The reaction mixture was filtered, and the filtrate was concentrated to dryness under reduced pressure. The mixture was purified by silica gel column chromatography and then by high pressure preparative liquid separation (Xtimate C18 column) to afford Example 40 (50 mg).

[0497] 1 H NMR(500MHz,DMSO-d6)δ7.95(d,J=9.2Hz,1H),7.80(d,J=8.3Hz,1H),7.73(d,J=8.5H z,2H),7.68(d,J=2.3Hz,1H),7.59(dd,J=9.2,2.4Hz,1H),7.54(t,J=7.9Hz,1H),7.1 3(t,J=8.8Hz,3H),5.14(s,1H),3.90(dd,J=9.2,6.9Hz,1H),3.76-3.68(m,2H),3.63 (d,J=6.1Hz,2H),3.40(dd,J=13.0,9.1Hz,1H),2.94-2.86(m,1H).HRMS(ESI+,[M+H] + )m / z:438.0989.

[0498] Example 41

[0499] Step A: To a single-necked flask, 34-6 (250 mg), MeOH (2 mL), THF (2 mL), H2O (1 mL) and sodium hydroxide (89 mg) were added in sequence. After the addition, the mixture was stirred at room temperature for 2 h. After the reaction, the reaction solution was poured into 20 mL of water and the pH was adjusted to 1-2 with 2M hydrochloric acid. The mixture was extracted with EA, and the organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent to obtain intermediate 41-1 (242 mg). MS (ESI-, [MH] - )m / z:415.20.

[0500] Step B: To a single-necked flask, 41-1 (227 mg), DCM (10 mL), N,O-dimethylhydroxylamine hydrochloride (150 mg), HATU (311 mg) and DIPEA (423 mg) were added in sequence. After the addition, the mixture was stirred at room temperature for 1 h. After the reaction, the reaction solution was poured into 20 mL of water, extracted with EA, and purified by silica gel column chromatography (MeOH / DCM) to obtain compound 41-2 (146 mg). MS (ESI+, [M+H] + )m / z:460.18.

[0501] Step C: To a single-necked flask, 41-2 (126 mg) and THF (5 mL) were added sequentially. Under N2 protection, the mixture was cooled to 0°C and 3M methylmagnesium bromide solution (0.27 mL) was added dropwise. After the addition was complete, the reaction mixture was stirred at room temperature overnight. After the reaction was completed, the reaction solution was slowly added to a saturated sodium bicarbonate solution (20 mL) under ice bath, extracted with EA, and purified by silica gel column chromatography (MeOH / DCM) to obtain intermediate 41-3 (88 mg). MS (ESI-, [MH] - )m / z:413.23.

[0502] Step D: To a single-necked flask, 41-3 (80 mg) and MeOH (3 mL) were added sequentially. Under N2 protection, the temperature was lowered to 0°C, and then sodium borohydride (80 mg) was added in batches. After the addition was complete, stirring was continued for 1 h. After the reaction was completed, the reaction solution was slowly poured into an ice-cold saturated ammonium chloride solution (20 mL), extracted with EA, and purified by silica gel column chromatography to obtain Example 41 (74 mg).

[0503] Example 41: 1 H NMR(500MHz,DMSO-d6)δ8.21-8.19(m,1H),7.85-7.82(m,2H),7.73-7.71(m,3H),7.49-7.46(m,1H),7.35-7.27(m,1H),7.14-7.12(m,2H),7.06 -7.04(m,1H),4.95-4.88(m,1H),4.04-3.98(m,1H),3.85-3.72(m,1H), 3.65-3.60(m,1H),3.56-3.51(m,1H),1.12-1.09(m,3H).MS(ESI+,[M+H] + )m / z:417.24.

[0504] Example 42 (42_A and 42_B)

[0505] Step A: 29 (500 mg), acetonitrile (20 mL), 2,2,6,6-tetramethylpiperidinyl oxide (291 mg), and iodophenyl diacetic acid (1.20 g) were added to a reaction flask in sequence and reacted at room temperature for 5.5 hours. Water (50 mL) was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give compound 42-1 (517 mg). MS (ESI-, [M+H] - )m / z:416.19.

[0506] Step B: Compound 42-1 (517 mg), dimethylhydroxylamine hydrochloride (338 mg), HATU (707 mg), and N,N-diisopropylethylamine (961 mg) were added to the reaction flask in sequence and reacted at room temperature for 21.5 hours. Water (50 mL) was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layers were combined and purified by silica gel column chromatography (PE / EA) to obtain compound 42-2 (280 mg). HRMS (ESI+, [M+Na] + )m / z:483.1139.

[0507] Step C: 42-2 (270 mg) and tetrahydrofuran (20 mL) were added to the reaction flask in sequence. Methylmagnesium bromide (3 M solution in tetrahydrofuran, 0.98 mL) was added dropwise under ice bath. The mixture was transferred to room temperature and reacted for 3.5 hours. Saturated aqueous ammonium chloride solution (50 mL) was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layers were combined and purified by silica gel column chromatography (PE / EA) to obtain compound 42-3 (170 mg). MS (ESI-, [M+H] - ) m / z:414.20.

[0508] Step D: 42-3 (160 mg) and methanol (1 mL) were added to the reaction flask in sequence. Sodium borohydride (146 mg) was added under ice bath and the mixture was transferred to room temperature for 2.5 hours. Saturated aqueous ammonium chloride solution (20 mL) was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layers were combined and purified by silica gel column chromatography to obtain compound 42 (150 mg). MS (ESI+, [M+H] + )m / z:418.21.

[0509] Step E: Compound 42 (150 mg) was subjected to high pressure preparative liquid separation (CHIRALART cellulose-SB column; carbon dioxide:ethanol = 82:18). The first eluting peak was Example 42_A (35 mg), and the last eluting peak was Example 42_B (35 mg).

[0510] Example 42_A: 1H NMR(500MHz,DMSO-d6)δ8.08(dd,J=9.2,2.3Hz,1H),8.01(d,J=2.3Hz,1H),7.95(d,J=9 .2Hz,1H),7.81(d,J=8.3Hz,1H),7.75-7.71(m,2H),7.54(t,J=7.9Hz,1H),7.16-7.12( m,3H),5.26(d,J=5.1Hz,1H),4.55(ddd,J=9.0,6.2,4.3Hz,1H),4.18(t,J=9.0Hz,1H), 4.07(dd,J=9.0,6.3Hz,1H),3.85-3.77(m,1H),1.13(d,J=6.4Hz,3H).HRMS(ESI+,[M+H] + )m / z:418.1269.

[0511] Example 42_B: 1 H NMR(500MHz,DMSO-d6)δ8.06(dd,J=9.2,2.3Hz,1H),8.00(d,J=2.2Hz,1H),7.95(d,J=9 .2Hz,1H),7.81(d,J=8.3Hz,1H),7.75-7.71(m,2H),7.54(t,J=7.9Hz,1H),7.17-7.11( m,3H),5.17(d,J=5.4Hz,1H),4.58(ddd,J=9.0,6.4,3.8Hz,1H),4.19(t,J=9.0Hz,1H), 3.99(dd,J=8.9,6.4Hz,1H),3.84-3.77(m,1H),1.17(d,J=6.4Hz,3H).HRMS(ESI+,[M+H] + )m / z:418.1269.

[0512] Example 43

[0513] Step A: To a reaction flask, add 43-1 (3.52 g), MeOH (50 mL), and potassium carbonate (6.78 g) in sequence. The temperature was lowered to 0°C, and then di-tert-butyl dicarbonate (6.41 g) was added portionwise. After addition, the mixture was stirred at room temperature overnight. After completion of the reaction, the reaction mixture was poured into 100 mL of water, extracted with EA, and purified by silica gel column chromatography (PE / EA) to obtain intermediate 43-2 (4.80 g). 1 H NMR (500MHz, DMSO-d6) δ3.65-3.60(m,2H),3.45-3.44(m,2H),2.42-2.36(m,2H),1.41(s,9H).

[0514] Step B: To a reaction flask, 43-2 (3.80 g), EA (80 mL), HO (80 mL), and ruthenium trichloride (0.23 g) were added sequentially. The temperature was lowered to 0°C, and sodium periodate (15.7 g) was then added portionwise. After addition, the mixture was stirred at room temperature overnight. After completion of the reaction, the reaction mixture was poured into 100 mL of water, extracted with EA, and purified by silica gel column chromatography (PE / EA) to obtain intermediate 43-3 (2.28 g). 1 H NMR (500MHz, DMSO-d6) δ4.10-4.04(m,2H),3.26-3.21(m,2H),1.46(s,9H).

[0515] Step C: To a reaction flask, 43-3 (330 mg) and 4M hydrogen chloride-dioxane solution (5 mL) were added sequentially and stirred at room temperature for 0.5 h. After the reaction, the reaction solution was directly concentrated to dryness to obtain intermediate 43-4 (181 mg). 1 H NMR (500MHz, DMSO-d6) δ8.12(s,1H),3.69-3.63(m,2H),2.90-2.83(m,2H).

[0516] Step D: Referring to the synthesis of Example 1, in Step B, 43-4 was used instead of 4-hydroxy-2-pyrrolidone to obtain Example 43 (56 mg).

[0517] 1 H NMR(500MHz,DMSO-d6)δ8.29-8.28(m,1H),8.06-8.01(m,2H),7.90-7.88(m,1H),7.75-7.73(m,2H),7.61 -7.58(m,1H),7.23-7.22(m,1H),7.17-7.15(m,2H),4.11-4.08(m,2H),2.84-2.75(m,2H).MS(ESI-,[MH] - )m / z:406.17.

[0518] Example 44

[0519] Step A: To a reaction flask were added 35 (300 mg) and dichloromethane (6 mL) in sequence. Diethylaminosulfur trifluoride (0.15 mL) was slowly added dropwise under an ice bath and allowed to react for 1.5 hours. Water (10 mL) was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate and purified by silica gel column chromatography to afford Example 44 (120 mg).

[0520] 1H NMR(500MHz,DMSO-d6)δ8.17(dd,J=9.3,2.2Hz,1H),7.89-7.82(m,2H),7.74(dd,J=16.0,8.4Hz,3H),7.50(dd,J=15 .3,7.4Hz,2H),7.13(d,J=8.4Hz,2H),7.06(d,J=7.5Hz,1H),4.18-4.07(m,2H),3.81-3.69(m,3H).HRMS(ESI-,[M+H] - )m / z:403.1072.

[0521] Example 45

[0522] Step A: Compound 45-1 (1.00 g), 1-fluoro-4-trifluoromethyl-benzene (3.68 g), cesium carbonate (7.30 g), and DMF (10 mL) were added sequentially to a microwave tube and heated to 120°C for 2 h. After the reaction, water was added and the mixture was extracted with ethyl acetate. The organic layers were combined and purified by silica gel column chromatography to afford compound 45-2 (1.45 g).

[0523] 1 H NMR (500MHz, DMSO-d6) δ8.35(d,J=2.0Hz,1H),7.90(d,J=9.0Hz,1H),7.85(d,J=8.4Hz,1H),7.74(d,J=8 .7Hz,2H),7.68(dd,J=9.0,2.0Hz,1H),7.63-7.60(m,1H),7.27(d,J=7.6Hz,1H),7.17(d,J=8.6Hz,2H).

[0524] Step B: Compound 45-2 (1.0 g), diethyl malonate (0.62 mL), n-butyldi(1-adamantyl)phosphine (78.0 mg), allylpalladium(II) chloride dimer (40.0 mg), cesium carbonate (1.78 g), and 1,4-dioxane (20 mL) were added to a reaction flask in sequence. The mixture was heated to 100°C under N2 protection and reacted for 8 h. After the reaction, water was added and the mixture was extracted with ethyl acetate. The organic layers were combined and purified by silica gel column chromatography to obtain compound 45-3 (370 mg). MS (ESI-, [MH] - )m / z:445.19.

[0525] Step C: Compound 45-3 (170 mg), bromoacetonitrile (91 mg), and THF (1 mL) were added sequentially to a single-necked flask under nitrogen protection. NaH (22.85 mg, 60% w / w) was added at 0°C, and then heated to 60°C for 1 h. After completion, the reaction was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layers were combined and purified by silica gel column chromatography to obtain compound 45-4 (130 mg). MS (ESI-, [MH] - )m / z:484.22.

[0526] Step D: Compound 45-4 (130 mg), cobalt chloride hexahydrate (127 mg), and methanol (2 mL) were added sequentially to a single-necked flask. Sodium borohydride (101 mg) was added portionwise at 0°C, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layers were combined and purified by silica gel column chromatography to obtain compound 45-5 (60 mg). MS (ESI-, [MH] - )m / z:442.18.

[0527] Step E: 45-5 (60 mg), anhydrous calcium chloride (15 mg), and THF (2 mL) were added sequentially to a single-necked bottle. Sodium borohydride (11 mg) was added portionwise at 0°C, and the mixture was stirred at room temperature for 1 h. After completion of the reaction, the mixture was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layers were combined and purified by silica gel column chromatography to obtain compound 45 (40 mg). MS (ESI-, [MH] - )m / z:400.23.

[0528] 1 H NMR (500MHz, DMSO-d6) δ8.07(d,J=1.9Hz,1H),7.87(d,J=8.9Hz,1H),7.84(d,J=8.3Hz,2H),7.72(d,J=8.6Hz,2H),7.67(dd,J=8.9,1.9Hz,1H),7.54(t, J=7.9Hz,1H),7.21(dd,J=7.6,1.0Hz,1H),7.12(d,J=8.5Hz,2H),5.07(t,J =5.3Hz,1H),3.87-3.79(m,1H),3.70-3.63(m,1H),3.29-3.23(m,1H),3.19- 3.10(m,1H),2.71-2.62(m,1H),2.48-2.38(m,1H).

[0529] Step F: Compound 45 (30 mg) was separated by supercritical fluid chromatography (CHIRALART Amylose-SA 5 μm 20*100 mm column; CO 2 -ethanol elution). The first eluting peak was 45_A (10 mg) and the second eluting peak was 45_B (10 mg).

[0530] 45_A:MS(ESI - ,[MH] - )m / z:400.26; 1 H NMR(500MHz,DMSO-d6)δ8.07(d,J=1.8Hz,1H),7.90-7.81(m,3H),7.75-7.69(m,2H),7. 67(dd,J=8.9,1.9Hz,1H),7.54(dd,J=8.3,7.5Hz,1H),7.21(dd,J=7.5,1.0Hz,1H),7.1 6-7.09(m,2H),5.07(t,J=5.3Hz,1H),3.84(dd,J=10.5,5.6Hz,1H),3.67(dd,J=10.4,5 .1Hz,1H),3.30-3.24(m,1H),3.19-3.10(m,1H),2.71-2.62(m,1H),2.47-2.38(m,1H).

[0531] 45_B:MS(ESI - ,[MH] - )m / z:400.25; 1 H NMR(500MHz,DMSO-d6)δ8.07(d,J=1.8Hz,1H),7.92-7.81(m,3H),7.74-7.70(m,2H),7. 67(dd,J=8.9,1.9Hz,1H),7.54(dd,J=8.2,7.5Hz,1H),7.21(dd,J=7.5,1.0Hz,1H),7.1 6-7.09(m,2H),5.07(t,J=5.3Hz,1H),3.84(dd,J=10.5,5.5Hz,1H),3.67(dd,J=10.4,5 .1Hz,1H),3.30-3.23(m,1H),3.19-3.10(m,1H),2.72-2.62(m,1H),2.47-2.37(m,1H).

[0532] Example 46

[0533] To a single-necked flask, 45-5 (70 mg), ethanol (2 mL), and aqueous sodium hydroxide solution (2 mL, 1 M) were added in sequence. The mixture was heated to 110°C under nitrogen for 1 h, then cooled to room temperature, and hydrochloric acid (1 mL, 4 M) was added. The mixture was extracted with ethyl acetate, and the organic layers were combined and purified by silica gel column chromatography to obtain compound 46 (27 mg). MS (ESI-, [MH] - )m / z:370.17.

[0534] 1 H NMR (500MHz, DMSO-d6) δ7.91-7.85(m,3H),7.83(d,J=8.2Hz,1H),7.72(d,J=8.5Hz,2H),7.55(t,J=7.9Hz,1H),7.44(dd,J=8.7,1.8H z,1H),7.22(d,J=7.5Hz,1H),7.12(d,J=8.5Hz,2H),3.74(t,J=9.1Hz,1H),3.45-3.33(m,2H),2.59-2.54(m,1H),2.26-2.15(m,1H).

[0535] Test Example 1: In vitro protein thermal stability

[0536] 1.1 hTEAD1

[0537] hTEAD1 protein stock was diluted to 50 ng / μl in phosphate-buffered saline (PBS). SYPRO Orange Dye (5000×) was diluted to 20× in DMSO. 16 μl of the hTEAD1 protein dilution was added to a 96-well plate. Then, different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to achieve final concentrations of 10 μM and 1 μM. Blank control wells (without protein) and negative control wells (with protein but with DMSO) were also set up in duplicate. Finally, 4 μl of 20× SYPRO Orange Dye was added to each well and the mixture was centrifuged. The PCR was run on a Roche LightCycler 480 fluorescence quantitative PCR instrument using the following program: 20°C for 15 s; 30°C to 90°C at 0.02°C / s; and 20°C for 15 s. Melting temperatures (Tm) were determined using LightCycler Thermal Shift Analysis software, and the melting temperature difference (ΔTm) was calculated.

[0538] 1.2 hTEAD2

[0539] hTEAD2 protein stock was diluted to 50 ng / μl in phosphate-buffered saline (PBS). SYPRO Orange Dye (5000×) was diluted to 20× in DMSO. 16 μl of the hTEAD2 protein dilution was added to a 96-well plate. Then, different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to achieve final concentrations of 10 μM and 1 μM. Blank control wells (without protein) and negative control wells (with protein but with DMSO) were also set up in duplicate. Finally, 4 μl of 20× SYPRO Orange Dye was added to each well and the mixture was centrifuged. The PCR was run on a Roche LightCycler 480 fluorescence quantitative PCR instrument using the following program: 20°C for 15 s; 30°C to 90°C at 0.02°C / s; and 20°C for 15 s. Melting temperatures (Tm) were determined using LightCycler Thermal Shift Analysis software, and the melting temperature difference (ΔTm) was calculated.

[0540] 1.3 hTEAD3

[0541] hTEAD3 protein stock was diluted to 50 ng / μl in phosphate-buffered saline (PBS). SYPRO Orange Dye (5000×) was diluted to 20× in DMSO. 16 μl of the hTEAD3 protein dilution was added to a 96-well plate. Then, different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to achieve final concentrations of 10 μM and 1 μM. Blank control wells (without protein) and negative control wells (with protein but with DMSO) were also set up in duplicate. Finally, 4 μl of 20× SYPRO Orange Dye was added to each well and the mixture was centrifuged. The PCR was run on a Roche LightCycler 480 fluorescence quantitative PCR instrument using the following program: 20°C for 15 s; 30°C to 90°C at 0.02°C / s; and 20°C for 15 s. Melting temperatures (Tm) were determined using LightCycler Thermal Shift Analysis software, and the melting temperature difference (ΔTm) was calculated.

[0542] 1.4 hTEAD4

[0543] hTEAD4 protein stock was diluted to 50 ng / μl in phosphate-buffered saline (PBS). SYPRO Orange Dye (5000×) was diluted to 20× in DMSO. 16 μl of the hTEAD4 protein dilution was added to a 96-well plate. Then, different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to achieve final concentrations of 10 μM and 1 μM. Blank control wells (without protein) and negative control wells (with protein but with DMSO) were also set up in duplicate. Finally, 4 μl of 20× SYPRO Orange Dye was added to each well and the mixture was centrifuged. The PCR was run on a Roche LightCycler 480 fluorescence quantitative PCR instrument using the following program: 20°C for 15 s; 30°C to 90°C at 0.02°C / s; and 20°C for 15 s. Melting temperatures (Tm) were determined using LightCycler Thermal Shift Analysis software, and the melting temperature difference (ΔTm) was calculated. ΔTm=Tm(experimental group)-Tm(blank group).

[0544] The disclosed compounds have good binding activity with proteins (TEAD1, TEAD2, TEAD3 and TEAD4 proteins).

[0545] Test Example 2: In vitro cell proliferation inhibitory activity

[0546] 2.1 NCI-H2452 cell proliferation inhibitory activity assay

[0547] Take NCI-H2452 (NF2 wild-type) human mesothelioma cells in good growth condition, collect them into a centrifuge tube, adjust the cell density to 4000 cells / mL, and inoculate them into 96-well plates (100μL / well). After culturing in a cell culture incubator for 24 hours, use a nanoliter pipette to add the compound to a final concentration of 10000nM-0.61nM, 2 replicates, and set up a control. After continuing to culture in the cell culture incubator for 168 hours, the detection reagent CCK-8 (manufacturer: Beijing Tongren Chemical, 10μL / well) was added. After incubation in the cell culture incubator for 2 hours, the absorbance value was measured at 450nm using a PerkinElmer Envision microplate reader. Four-parameter analysis was performed, the dose-effect curve was fitted, and the IC was calculated. 50 .

[0548] 2.2 NCI-H226 cell proliferation inhibitory activity assay

[0549] Take NCI-H226 (NF2-deficient) human lung squamous cell carcinoma cells in good growth condition, collect them into centrifuge tubes, adjust the cell density to 4000 cells / mL, inoculate them into 96-well plates (100μL / well), and culture them in a cell culture incubator for 24 hours. Use a nanoliter pipette to add compounds to a final concentration of 10000nM-0.61nM, 2 replicates, and set up controls at the same time. After continuing to culture in the cell culture incubator for 168 hours, the detection reagent CCK-8 (manufacturer: Beijing Tongren Chemical, 10μL / well) was added. After incubation in the cell culture incubator for 2 hours, the absorbance value was detected at 450nm using a PerkinElmer Envision microplate reader. Four-parameter analysis was performed, and the dose-effect curve was fitted to calculate the IC 50 .

[0550] 2.3 NCI-H2052 cell proliferation inhibitory activity assay

[0551] Take NCI-H2052 (NF2 homologous mutation) human mesothelioma cells in good growth condition, collect them into a centrifuge tube, adjust the cell density to 4000 cells / mL, inoculate them into 96-well plates (100μL / well), and culture them in a cell culture incubator for 24 hours. Use a nanoliter pipette to add the compound to a final concentration of 10000nM-0.61nM, 2 replicates, and set up a control. After continuing to culture in the cell culture incubator for 168 hours, the detection reagent CCK-8 (manufacturer: Beijing Tongren Chemical, 10μL / well) was added. After incubation in the cell culture incubator for 2 hours, the absorbance value was measured at 450nm using a PerkinElmer Envision microplate reader. Four-parameter analysis was performed, and the dose-effect curve was fitted to calculate the IC 50 .

[0552] The test results of some compounds disclosed in the present invention are shown in Table 1.

[0553] Table 1 Results of in vitro cell proliferation inhibition experiment

[0554] The test results show that the disclosed compounds have proliferation inhibitory activity against NCI-H226 cells and NCI-H2052 cells, but have essentially no proliferation inhibitory activity against NCI-H2452 cells. They have good selectivity for NCI-H226 and NCI-H2052 cells relative to NCI-H2452 cells.

[0555] Test Example 3: In vitro liver microsome stability

[0556] Liver microsomal incubation samples were prepared by mixing PBS buffer (pH 7.4), liver microsomal solution (0.5 mg / mL), test compound, and NADPH + MgCl₂ solution at 37°C and 300 rpm for 1 hour. The 0-hour sample was prepared by mixing PBS buffer (pH 7.4), liver microsomal solution (0.5 mg / mL), and test compound. The sample was added to acetonitrile containing an internal standard for protein precipitation, and the supernatant was prepared and diluted for LC / MS / MS analysis. Results for selected compounds are shown in Table 2.

[0557] Table 2

[0558] The experimental results show that the compounds disclosed herein are stable in the in vitro hepatic microsome metabolism.

[0559] Test Example 4: In vivo pharmacokinetics

[0560] 4.1 Pharmacokinetics in mice

[0561] ICR mice weighing 18-22 g were randomly divided into groups of 9 after acclimation for 3-5 days and were orally administered with a solution of the test compound at a dose of 10 mg / kg (or 2 mg / kg).

[0562] Blood was collected from the eye socket at 15 min, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h to prepare plasma samples for testing.

[0563] 30 μL of plasma sample to be tested and standard curve sample were taken, and acetonitrile solution containing internal standard was added to obtain protein precipitation to obtain supernatant, which was diluted and used for LC / MS / MS determination.

[0564] The pharmacokinetic parameters were fitted using a non-compartmental model. The results for some compounds disclosed herein are shown in Table 3.

[0565] Table 3

[0566] The experimental results show that the disclosed compounds have good pharmacokinetic properties in mice (such as AUC, T 1 / 2 、C max The absolute bioavailability was greater than 90%.

[0567] 4.2 Pharmacokinetics in rats

[0568] SD rats weighing 180-220 g were randomly divided into groups of 3 after acclimation for 3-5 days and administered the test compound solution at the corresponding dose. Blood was collected from the eye socket at 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24, 30, and 48 hours. Plasma samples were prepared. 30 μL of the test plasma sample and the standard curve were aspirated and protein precipitated with acetonitrile containing an internal standard. The supernatant was diluted and used for LC / MS / MS analysis. Pharmacokinetic parameters were fitted using a non-compartmental model.

[0569] The experimental results show that the disclosed compounds also have good pharmacokinetic properties in rats (such as AUC, T 1 / 2 、C max The absolute bioavailability was greater than 90%.

[0570] Test Example 5: In vivo efficacy

[0571] Pharmacodynamic evaluation of the NCI-H226 human lung squamous cell carcinoma subcutaneous xenograft model in nude mice

[0572] SPF female nude mice (source: Shanghai Bikeway Biotechnology Co., Ltd.) were subcutaneously inoculated with NCI-H226 cells (5×10⁶ cells / mouse) in the right axilla. When the average tumor volume reached approximately 150 mm⁻, the animals were divided into groups.

[0573] The day of grouping was designated Day 0. Starting from Day 0, drugs were administered by gavage daily. Tumor volume was measured twice weekly, and mice were weighed and recorded. General performance of the mice was observed and recorded daily. At the end of the experiment, tumors were removed, weighed, and photographed.

[0574] The detection indicators and calculation formulas are as follows:

[0575] Tumor volume, TV (mm 3 )=1 / 2×(a×b 2 ), where a is the long diameter of the tumor and b is the short diameter of the tumor.

[0576] Relative tumor volume, RTV = TV t / TV0; TV0 is the tumor volume on day 0, TV t is the tumor volume at each measurement.

[0577] Relative tumor growth rate, T / C (%) = T RTV / C RTV ×100%; where T RTV RTV for the treatment group; C RTV The vehicle control group was RTV.

[0578] Tumor growth inhibition rate, TGI (%) = (1-TW / TW0) × 100%; wherein, TW is the tumor weight of the treatment group, and TW0 is the tumor weight of the vehicle control group.

[0579] Body weight change rate, WCR (%) = (Wt t -Wt0) / Wt0×100%; where Wt0 is the weight of mice on day 0, Wt t is the weight of the mice at each measurement.

[0580] The test results show that the disclosed compounds can effectively inhibit tumor growth in mice (e.g., parameters such as T / C or TGI (%) show results of effective inhibition of tumor growth).

Claims

1. A compound of formula IC, or a pharmaceutically acceptable salt thereof, in, X 1 , X 2 , X 3 , X 4 and X 5 are independently selected from N or CH; X a , X b , X c , X d , X e and X f are each independently selected from N or CH optionally substituted by a substituent; X is selected from O, S, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, or the following groups optionally substituted by one or more substituents: NH, -N(C 1-6 Alkyl)-, -NH-C 1-6 Alkyl-, -C 1-6 Alkyl-O-, -C 1-6 Alkyl-S- or -C(O)NH-; Every R 1 are independently selected from CN, halogen, or the following groups optionally substituted by one or more substituents: C 1-6 Alkyl, C 2- 6-alkenyl, C 2-6 Alkynyl, R'O-, R'S-, -SF5, R'R”N-, R'OC(O)-, R'C(O)O-, -C(O)NR'R”, R'C(O)NH-, R' S(O)NH-, R'R”NS(O)-, R’S(O)2NH-, R’R”NS(O)2-, R’OC(O)NH-, R’R”NC(O)O-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3- 12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; Every R 2 are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R'O-, R'S-, -SF5, R'R”N-, R'OC(O)-, R'C(O)O-, -C(O)NR'R”, R'C(O)NH-, R'R”NS(O)-, R' S(O)NH-, R'R”NS(O)-, R'R”NS(O)2-, R’S(O)2NH-, R’R”NS(O)2-, R’OC(O)NH-, R’R”NC(O)O-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; R' and R" are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; m and n are independently selected from 0, 1, 2, 3, 4 or 5; Ring A is selected from 3-12 membered heterocycloalkyl or 3-12 membered heterocycloalkenyl.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from a compound of formula I, or a pharmaceutically acceptable salt thereof, in, X 1 , X 2 , X 3 , X 4 and X 5 are independently selected from N or CH; X a , X b , X c , X d , X e and X f are each independently selected from N or CH optionally substituted by a substituent; X is selected from O, S, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, or the following groups optionally substituted by one or more substituents: NH, -N(C 1-6 Alkyl)-, -NH-C 1-6 Alkyl-, -C 1-6 Alkyl-O-, -C 1-6 Alkyl-S- or -C(O)NH-; Every R 1 are independently selected from CN, halogen, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1- 6 alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl)2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; Every R 2 are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, C 1-6 AlkylNHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl)2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; m and n are independently selected from 0, 1, 2, 3, 4 or 5; Ring A is selected from 3-12 membered heterocycloalkyl or 3-12 membered heterocycloalkenyl.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein X 1 , X 2 , X 3 , X 4 and X 5 are independently selected from N or CH; Or, X 1 , X 2 , X 3 , X 4 and X 5 are independently selected from N or CH, X 1 , X 2 , X 3 , X 4 and X 5 Optionally one or two of them are selected from N; Or, X 1 , X 2 , X 3 , X 4 and X 5 are independently selected from N or CH, X 1 , X 2 , X 3 , X 4 and X 5 One of them is selected from N; Or, X 1 , X 2 , X 3 , X 4 and X 5 are independently selected from N or CH, X 1 , X 2 , X 3 , X 4 and X 5 Two of them are selected from N; Or, X 1 , X 2 , X 3 , X 4 and X 5 Selected from CH.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein X a , X b , X c , X d , X e and X f are independently selected from N or optionally one or more R a substituted CH, the R a Selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2- 6-alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 alkyl)2N-; or, X a , X b , X c , X d , X e and X f are independently selected from CH or N; Or, X a , X b , X c , X d , X e and X f are independently selected from CH or N, X a , X b , X c , X d , X e and X f Optionally one or two of them are selected from N; Or, X a , X b , X c , X d , X e and X f Selected from CH; Or, X b , X d , X e and X f are independently selected from CH, X a and X c are independently selected from CH or N, wherein CH is optionally replaced by an R a replace; Or, X b , X d , X e and X f are independently selected from CH, X a and X c are independently selected from CH or N; Optionally, the R a Selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl) 2N-, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH- or (C 1-6 alkyl)2N- is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1- 3 alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1-3 Alkyl)2N-; Alternatively, the R a Selected from CN, halogen, OH, NH2 or C 1-3 alkyl.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein X is selected from O, S, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, or the following groups optionally substituted with one or more substituents: NH, -N(C 1-3 Alkyl)-, -NH-C 1-3 Alkyl-, -C 1-3 Alkyl-O-, -C 1-3 Alkyl-S- or -C(O)NH-; Alternatively, X is selected from O, S, or the following groups optionally substituted by one or more substituents: NH or -N(C 1-3 alkyl)-; Alternatively, X is selected from O, S, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, NH, -N(C 1-6 Alkyl)-, -NH-C 1-6 Alkyl-, -C 1-6 Alkyl-O-, -C 1-6 Alkyl-S- or -C(O)NH-; Alternatively, X is selected from O, S, NH, -N(C 1-3 Alkyl)-, -NH-C 1-3 Alkyl-, -C 1-3 Alkyl-O-, -C 1-3 Alkyl-S-, -S(O)-, -S(O)2-, -C(O)-, -C(O)NH- or -C(O)O-; Alternatively, X is selected from O, S, NH or -N(C 1-3 alkyl)-; Alternatively, X is selected from O, S or NH; Alternatively, X is selected from O.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R' and R" are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl; Alternatively, R' and R" are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl; Alternatively, R' and R" are independently selected from hydrogen or C 1-3 alkyl; Alternatively, R' and R" are each independently selected from hydrogen, methyl, -CH2CH2NH2 or ethyl.

7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein each R 1 are independently selected from CN, halogen, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, HOC(O)-, C 1-6 Alkyl OC(O)-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 AlkylNHC(O)-, C 1-6 Alkyl C(O)NH-, (C 1-6 Alkyl)2NC(O)-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; Or, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1- 6-alkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1- 6 alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; Or, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1- 6-alkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1- 6 alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl)2N-; Or, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1- 6-alkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl)2N-; Or, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1- 3 alkyl) 2N-; Or, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH- or (C 1-6 Alkyl) 2N-, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, C 1-6 Alkyl NH- or (C 1-6 alkyl)2N- is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl O-, C 1-3 Alkyl S-, -SF5, C 1-3 Alkyl NH- or (C 1-3 Alkyl)2N-; Or, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH- or (C 1-4 Alkyl) 2N-, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH- or (C 1-4 alkyl)2N- is optionally substituted with one or more of the following: CN, halogen, OH or NH2; Or, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl or -SF5, the C 1-4 Alkyl, C 2-4 Alkenyl or C 2-4 Alkynyl is optionally substituted with one or more of the following: CN, halogen, OH or NH2; Or, each R 1 are independently selected from CN, halogen, OH, NH2, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl or -SF5, the C 1-3 Alkyl, C 2-3 Alkenyl or C 2-3 Alkynyl is optionally substituted with one or more of the following: CN, halogen, OH or NH2; Or, each R 1 are independently selected from CN, halogen, OH, NH2 or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: CN, halogen, OH or NH2; Or, each R 1 Each independently selected from halogenated C 1-6 Alkyl or -SF5; Or, each R 1 Each independently selected from halogenated C 1-3 Alkyl or -SF5; Or, each R 1 Each independently selected from fluorinated C 1-3 Alkyl or -SF5; Or, each R 1 Each independently selected from fluorinated C 1-3 alkyl; Or, each R 1 Each independently selected from CF3 or -SF5; Or, each R 1 are each independently selected from CF3.

8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein each R 2 are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R'O-, R'S-, -SF5, R'R”N-, R'OC(O)-, R'C(O)O-, -C(O)NR'R”, R'C(O)NH-, R'R”NS(O)-, R' S(O)NH-, R'R”NS(O)-, R'R”NS(O)2-, R’S(O)2NH-, R’R”NS(O)2-, R’OC(O)NH-, R’R”NC(O)O-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R'O-, R'S-, -SF5, R'R”N-, R'OC(O)-, R'C(O)O-, -C(O)NR'R”, R'C(O)NH-, R'R”NS(O)-, R'S(O) NH-, R'R”NS(O)-, R'R”NS(O)2-, R’S(O)2NH-, R’R”NS(O)2-, R’OC(O)NH-, R’R”NC(O)O-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted by one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-,R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; Or, each R 2 are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, HOC(O)-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; Or, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, HOC(O)-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1- 6 alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted by one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2- 6-alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-,R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; Or, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, HOC(O)-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted by one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-; Or, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, HOC(O)-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, -C(O)NH2, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 1-4 AlkylNHS(O)-, C 1-4 Alkyl S(O)NH-, (C 1-4 Alkyl)2NS(O)-, C 1-4 AlkylNHS(O)2-, C 1-4 Alkyl S(O)2NH-, (C 1-4 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 1-4 AlkylNHS(O)-, C 1-4 Alkyl S(O)NH-, (C 1-4 Alkyl)2NS(O)-, C 1-4 AlkylNHS(O)2-, C 1-4 Alkyl S(O)2NH-, (C 1-4 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted by one or more of the following groups: CN, halogen, C 1-4 Alkyl, C 2-4 Olefin Base, C 2-4 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-; Or, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, HOC(O)-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, -C(O)NH2, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, (C 1-4 Alkyl)2N-, C 1-4 Alkyl NH-, -COOH, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylCONH-, C 1-4 Alkyl NHCO- or (C 1-4 Alkyl)2NHCO-; Or, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 1-4 Alkyl O-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, HOC(O)-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, -C(O)NH2, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-4 Alkyl, C 1-4 Alkyl O-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl NH-, -COOH, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-; Or, each R 2 are independently selected from CN, halogen, =O, OH, NH2, C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, HOC(O)-, C 1-3 Alkyl OC (O) -, -C (O) NH2 or 5-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, C 1-3 Alkyl OC (O) - or 5-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl, -C 1-3 Alkyl NH-, COOH, or C 1-3 AlkylOC(O)-; Or, each R 2 are independently selected from CN, halogen, =O, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, HOC(O)-, CH3OC(O)-, CH3CH2OC(O)-, -C(O)NH2 or 5-membered oxygen-containing heterocycloalkyl, wherein the methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, methyl, -COOH, C 1-2 Alkyl NH- or CH3OC(O)-; Or, each R 2 Each of the following is independently selected from CN, halogen, =O, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, HOC(O)-, CH3OC(O)-, CH3CH2OC(O)-, -C(O)NH2 or a 5-membered oxygen-containing heterocycloalkyl, wherein the methyl, ethyl, CH3CH2NH- or a 5-membered oxygen-containing heterocycloalkyl is optionally substituted with one or more of the following groups: halogen, OH, NH2, methyl, -COOH, CH3NH- or CH3OC(O)-; Or, each R 2 are independently selected from halogen, =O, OH, NH2, -CH3, -CH2OH, -CH2F, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2C(O)OCH3, -CH2C(O)OH, -CH2NH2, -CH2NHCH3, -OCH3, -NHCH3, -NHCH2CH2NH2, -C(O)OH, -C(O)OCH3, -C(O)OCH2CH3, -C(O)NH2 or Optionally, R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl; Or, R b and R c are independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl; Or, R b and R c are independently selected from hydrogen or C 1-3 alkyl.

9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein m and n are independently selected from 0, 1, 2 or 3; Alternatively, m and n are independently selected from 1 or 2; Alternatively, m is selected from 1; Optionally, n is selected from 1 or 2.

10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein ring A is selected from a 3-10 membered heterocycloalkyl or a 3-10 membered heterocycloalkenyl; Alternatively, Ring A is selected from 3-10 membered heterocycloalkyl or 3-8 membered heterocycloalkenyl; Alternatively, ring A is selected from 4-10 membered heterocycloalkyl; Alternatively, ring A is selected from 4-8 or 10-membered heterocycloalkyl; Alternatively, ring A is selected from 4-6 membered monocyclic heterocycloalkyl, 7-8 membered or 10 membered spiroheterocycloalkyl; Alternatively, Ring A is selected from 5-membered monocyclic heterocycloalkyl; Alternatively, ring A is selected from pyrrolidinyl, thiazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, diazaspirodecanyl, monooxa-azaspirooctanyl, azetidinyl, monoazaspiroheptyl or oxazolidinyl; Alternatively, ring A is selected from Where X t is selected from CH2, NH or O.

11. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein the compound of formula I or a pharmaceutically acceptable salt thereof is selected from a compound of formula IC-1, IC-2, IC-3, IA, IA-1, IA-2, IA-3, II, II-1, II-2, II-3, III, IV, IIIA, IVA, V, VI or VII, or a pharmaceutically acceptable salt thereof, in, q is selected from 0, 1, 2 or 3; X a and X c are independently selected from CH or N; X 6 Selected from N or CH, X 7 is selected from NH, O, S or CH2, and X 6 and X 7 At least one of them contains a nitrogen atom; Ring B is selected from 3-10 membered heterocycloalkyl or 3-10 membered heterocycloalkenyl; Every R 2a are independently selected from CN, halogen, =O, or the following groups optionally substituted by one or more substituents: OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, HOC(O)-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, -C(O)NH2, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1- 6-AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; p is selected from 0, 1, 2 or 3; T is selected from S=O or C; X t is selected from CH2, NH or O.

12. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein ring B is selected from a 3-8 membered heterocycloalkyl or a 3-8 membered heterocycloalkenyl; Alternatively, Ring B is selected from 3-6 membered heterocycloalkyl or 3-6 membered heterocycloalkenyl; Alternatively, Ring B is selected from 3-10 membered heterocycloalkyl; Alternatively, Ring B is selected from 4-10 membered heterocycloalkyl; Alternatively, Ring B is selected from 4-8 or 10-membered heterocycloalkyl; Alternatively, Ring B is selected from 4-6 membered monocyclic heterocycloalkyl, 7-8 membered or 10 membered spiroheterocycloalkyl; Alternatively, Ring B is selected from 4-8 membered heterocycloalkyl; Alternatively, Ring B is selected from 4-6 membered heterocycloalkyl; Alternatively, Ring B is selected from 5-6 membered heterocycloalkyl; Alternatively, ring B is selected from pyrrolidinyl, thiazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, diazaspirodecanyl, monooxa-azaspirooctanyl, azetidinyl, monoazaspiroheptyl or oxazolidinyl; Optionally, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1- 6-alkylNHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1- 6-alkylNHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted by one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-,R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocycloalkyl, C 3-12 Cycloalkenyl, 3-12 membered heterocycloalkenyl, C 6-12 Aryl or 5-12 membered heteroaryl; Or, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl O-, C 1-6 Alkyl S-, -SF5, C 1-6 Alkyl NH-, (C 1-6 Alkyl)2N-, C 1-6 Alkyl OCO-, C 1-6 Alkyl C(O)O-, C 1-6 Alkyl NHCO-, C 1-6 AlkylCONH-, (C 1-6 Alkyl)2NCO-, C 1-6 AlkylNHS(O)-, C 1-6 Alkyl S(O)NH-, (C 1-6 Alkyl)2NS(O)-, C 1-6 AlkylNHS(O)2-, C 1-6 Alkyl S(O)2NH-, (C 1-6 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted by one or more of the following groups: CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-; Or, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 1-4 AlkylNHS(O)-, C 1-4 Alkyl S(O)NH-, (C 1-4 Alkyl)2NS(O)-, C 1-4 AlkylNHS(O)2-, C 1-4 Alkyl S(O)2NH-, (C 1-4 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 1-4 AlkylNHS(O)-, C 1-4 Alkyl S(O)NH-, (C 1-4 Alkyl)2NS(O)-, C 1-4 AlkylNHS(O)2-, C 1-4 Alkyl S(O)2NH-, (C 1-4 Alkyl)2NS(O)2-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl are optionally substituted by one or more of the following groups: CN, halogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, R b O-、R b S-、-SF5、R b R c N-、R b OC(O)-、R b C(O)O-、R b CONH-, R b R c NCO-, R b S(O)NH-、R b R c NS(O)-、R b S(O)2NH- or R b R c NS(O)2-; Or, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-4 Olefin Base, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, -SF5, (C 1-4 Alkyl)2N-, C 1-4 Alkyl NH-, -COOH, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylCONH-, C 1-4 Alkyl NHCO- or (C 1-4 Alkyl)2NHCO-; Or, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-4 Alkyl, C 1-4 Alkyl O-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkyl O-, C 1-4 Alkyl S-, C 1-4 Alkyl NH-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-, C 1-4 AlkylNHC(O)-, C 1-4 Alkyl C(O)NH-, (C 1-4 Alkyl)2NC(O)-, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1- 4 alkyl, C 1-4 Alkyl O-, (C 1-4 Alkyl)2N-, C 1-4 Alkyl NH-, -COOH, C 1-4 Alkyl OC(O)-, C 1-4 Alkyl C(O)O-; Or, each R 2a are independently selected from CN, halogen, =O, OH, NH2, C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, C 1-3 Alkyl OC (O) - or 5-6 membered heterocycloalkyl, the C 1-3 Alkyl, C 1-3 Alkyl O-, C 1-3 Alkyl NH-, C 1-3 Alkyl OC (O) - or 5-6 membered heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, C 1-3 Alkyl, -COOH, or C 1-3 AlkylOC(O)-; Or, each R 2a Each of the following is independently selected from CN, halogen, =O, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl, wherein the methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: CN, halogen, OH, NH2, methyl, -COOH, or CH3OC(O)-; Or, each R 2a Each of them is independently selected from CN, halogen, =O, OH, NH2, methyl, ethyl, CH3O-, CH3NH-, CH3CH2NH-, CH3OC(O)-, CH3CH2OC(O)- or a 5-membered oxygen-containing heterocycloalkyl, wherein the methyl, ethyl, CH3CH2NH- or a 5-membered oxygen-containing heterocycloalkyl is optionally substituted by one or more of the following groups: halogen, OH, NH2, methyl, -COOH, or CH3OC(O)-; Or, each R 2a are independently selected from halogen, =O, OH, NH2, -CH3, -CH2OH, -CH2F, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2C(O)OCH3, -CH2C(O)OH, -OCH3, -NHCH3, -NHCH2CH2NH2, -C(O)OCH3, -C(O)OCH2CH3 or Optionally, p is selected from 0, 1 or 2; Optionally, R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 3-6 Cycloalkenyl, 3-6 membered heterocycloalkenyl, C6 aryl or 5-6 membered heteroaryl; Or, R b and R c are independently selected from hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl; Or, R b and R c are independently selected from hydrogen or C 1-3 alkyl.

13. The following compound, or a pharmaceutically acceptable salt thereof:

14. A pharmaceutical composition comprising the compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, and optionally, a pharmaceutically acceptable excipient.

15. Use of the compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 14 in the preparation of a medicament for preventing or treating a disease; optionally, the disease is selected from cancer.

Citation Information

Patent Citations

  • Pyrido[2,3-b]pyrazine-8-substituted compounds and their use

    CN101945869A

  • Therapeutic uses of heterocyclic compounds as kinase inhibitors

    CN114025755A

  • Bicyclic compounds

    CN114072207A

  • Quinoline derivatives as protein kinase inhibitors

    CN114391009A

  • Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use

    US20100016293A1